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1 Abstract 
 
The identification of the functional neuronal circuitry involved in a given process still 
remains a crucial scientific challenge in anatomical Neuroscience. The development of the 2-
Deoxyglucose technique (2DG) provided the first, and only, non-invasive strategy for 
identification of metabolically active neurons. However, the inability to distinguish metabolised 
2DG in stimulus-responsive neurons from unmetabolised 2DG has made the desire for novel 
tools to elucidate neuronal circuit organisation unfulfilled.  
Here we present a genetically encoded calcium “Integrator” that labels active neuron 
ensembles with an irreversible change in fluorescence. This calcium integrator represents the 
first genetically encoded neuroanatomical biosensor for the identification of functional 
anatomical circuits.  
In order to generate the calcium Integrator three architectural approaches were 
undertaken; i) a calcium-dependent protease FRET integrator, ii) an artificial calcium-dependent 
protease FRET integrator and iii) a “Bimolecular Fluorescence Complementation”-based 
Integrator. Of these three approaches the complementation Integrator has been engineered to 
yield the first biosensor, with an EC50 of 420 nM, which is responsive to endogenous cellular 
calcium transients. Furthermore, the application of a virus-induced Integrator in cell culture 
yield a maximal 1580 % increase in fluorescence, after 4 hour stimulation using simulated 
physiological firing patterns, and has successfully been shown to differentiate between 
different neuronal firing patterns. In addition the criteria needed for split-protein biosensor 
development has been highlighted with an additional demonstration that complementation can 
be applied for the development of alternative split-protein based strategies.   
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2 Introduction 
 
Since the foundation of anatomical neuroscience was laid by Golgi and Ramón y Cajal, 
significant efforts have been made to improve our understanding of neuroanatomical 
architecture and neuronal circuits.  In recent years, the popularity of genetically encoded 
methodologies utilising Fluorescent Proteins (FPs) has provided researchers with an 
unprecedented ability to study large populations of neurons simultaneously. Despite the 
generation of many genetically encoded biosensors directed towards monitoring cellular 
processes such as dynamic signalling processes, biochemical events, and protein-protein 
interactions, there is a growing desire to apply non-invasive genetically encoded methodologies 
to unravel neuroanatomical architecture and circuits. Notable methodologies such as 
“Brainbow” (Livet et al., 2007) and “Transynaptic Tracers” (Wickersham et al., 2007) that utilise 
FPs to resolve neuronal architectures with high spatial resolution, have opened a window into 
this research field. However, the tools available for investigating functional neuroanatomical 
circuits are insufficient with the only tool available being that of the non-genetically encoded 2-
Deoxyglucose method (Sokoloff et al., 1977). This method has enabled the labelling of large 
populations of metabolically active neurons; albeit with poor spatial resolution. Thus, the 
application of genetically encoded methodologies for the identification of functional 
neuroanatomical circuits would undoubtedly achieve an improvement in resolution and grant 
significant insight into the structure of functional neuronal circuits. Furthermore, it would 
provide a valuable method for the study of circuitry with a single cell resolution.   
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2.1 2-deoxyglucose (2DG) 
To date, the 2-deoxyglucose (2DG) histochemical technique is the only method that 
labels large populations of neurons with an irreversible signal output (Sokoloff et al., 1977). By 
administration of radiolabelled 2DG (2-deoxy-D-[14C] glucose) to conscious animals active 
neuron ensemble can be labelled due to the exchange of glucose between the cerebral 
ventricles and the surrounding tissue. Once integrated into metabolically active cells the 2DG is 
phosphorylated by hexokinase to 2-deoxyglucose-6-phosphate (2DG-6P) whereby it is unable to 
undergo further metabolism and therefore confined in the cell until autoradiographic 
detection.  Since its initial development 2DG has enjoyed significant application as the only 
technique for neuronal network determination to presented stimuli. For example, the 2DG 
technique has been eloquently demonstrated in the fly optic lobe (Figure 1A) where it has 
provided whole brain structural resolution comparable to silver stain techniques (Figure 1 B,C) 
(Fischbach and Dittrich, 1989; Bausenwein and Fischbach, 1992).  
However, with a poor spatial resolution of 100 µm this technique prevents individual 
neuron identification (Kai Kai and Pentreath, 1981). Optimisation of the 2DG method primarily 
focused on improving the spatial resolution through the replacement of the 14C label with 3H 
(Figure 1D) (Des Rosiers and Descarries, 1978). In addition Durham and colleagues further 
improved the resolution via the combination of 3H-2DG with paraffin histology and emulsion 
autoradiography, successfully eliminating film autoradiography and necessity for unfixed tissue 
samples (Durham et al., 1981). These improvements significantly enhancing the resolution that 
enabled 2DG use with: conventional and electron microscopy (EM) (Kai Kai and Pentreath, 
1981), double-labelling immunohistochemistry (McCasland, 1996), and whole brain 
reconstructions using autoradiographic sections (Kim et al., 1995). 
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Figure 1: 2-Deoxyglucose (2DG) autoradiography  
A) Schematic of the Drosophila melanogaster optic lobe (Borst et al., 2010). B) Holmes-Blest silver 
stained horizontal section of the fly optic lobe (LO: Lobula, LP: Lobula Plate, ME: Medulla, LA Lamina 
(Adapted from (Fischbach and Dittrich, 1989)). C) [14C] 2-DG labeling of the fly optic lobe (Bausenwein 
and Fischbach, 1992). D) Dry-mount autoradiogram from the mouse ventrolateral medulla after 
injection of [3H] 2-DG showing single cell labeling (Duncan et al., 1990). 
 
Despite the success of this method, a discrepancy remains between signal output and 
neuronal activity. Fundamentally this problem arises due to the inability to distinguish between 
phosphorylated and unphosphorylated 2DG, and the variation in processed label intensity. The 
lack of distinction between the metabolised 2DG-6P product and the unmetabolised 2DG within 
the cell constitutes a major issue in neuronal activity determination. Transport of glucose/2DG 
into cells had been shown to occur at a much higher rate than phosphorylation; thus without an 
adequate method for distinguishing phosphorylated from unphosphorylated 2DG the degree of 
neuronal activity cannot be reliably determined (Lund-Andersen, 1979). In addition, the level of 
signal attained can display high degrees of variability depending on handling and fixation 
methodology. For example, comparison by Kai et al. of glutaraldehyde fixed tissue from three 
different research groups found that the amount of label retained by the tissue varied from 
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10% to 90% (Kai Kai and Pentreath, 1981) . This not only highlights the signal variability when 
using 2DG but also the unsuitability for comparing 2DG results from different sources. Finally, 
even with technical improvements, the discovery that 2DG could be used to reduce epilepsy 
progression by acting as a glycolytic inhibitor (Garriga-Canut et al., 2006) brings into serious 
doubt the physiological validity of applying 2DG to study neuronal network function. It is most 
likely the case that 2DG application has a significant impact on neuronal function and 
communication. Despite this, 2DG is still widely used for metabolic activity imaging with several 
fluorodeoxyglucose analogs (18F-FDG) available that are, for example, used in combination with 
Computed tomography (CT) for the identification of tumours in mice (Kovar et al., 2009) or the 
identification of epileptic foci (Tsytsarev et al., 2012). 
 
2.2 Genetically encoded biosensor mechanisms 
Since the initial discovery of the Green Fluorescent Protein (GFP) from Aequorea 
Victoria (Shimomura et al., 1962), and the subsequent sequence identification and expression 
in E.coli and C.elegans (Prasher et al., 1992; Chalfie et al., 1994), GFP has revolutionised  the Life 
Sciences. Comprising of a S65-Y66-G67 chromophore surrounded by an 11-stranded β-barrel 
structure (Ormö et al., 1996; Yang et al., 1996), GFP has been the subject of almost two decades 
of structural improvement and spectral diversification (Chudakov et al., 2010 provides a recent 
comprehensive review) that has resulted in a multitude of FP variants leading to a range of 
genetically encoded biosensors.  
Genetically encoded biosensors based on GFP have been generated to monitor many 
cellular events with the objective of converting a molecular event into a designated signal 
output detectable via fluorescence microscopy. Genetically encoded biosensors confer many 
advantages over other probes designed for monitoring cellular events (such as Ca2+ dyes) 
including the diversity of application, the capacity for targeted biosensor expression (for 
example targeting to subcellular targets, or cell-specific expression) and the ability to undertake 
chronic imaging. Furthermore, as genetically encoded biosensors are genetically expressed 
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external application is not required unlike synthetic probes that require either application via 
injection of individual cells or administration to a localised area whereby the dye is 
incorporated into the cells via diffusion (Tsien, 1981). This limits not only the number of cells 
visualized but also imposes a time limit for which the investigation can proceed. Genetically 
encoded biosensors on the other hand can be expressed stably (either by transient 
transfection, viral infection or transgenic expression) and can be studied for weeks without 
notable loss of signal. The mechanisms by which genetically encoded biosensors yield a 
detectable signal can be divided into single fluorophore biosensors, Fluorescence Resonance 
Energy Transfer (FRET) biosensors, and split-protein biosensors (Figure 2). In principle, 
genetically encoded biosensors belong to two categories defined by the type of signal 
generated. The first category, the reversible biosensors, consists of the majority of single 
fluorescence biosensors and FRET biosensors; whereas the second category, the irreversible 
biosensors, primarily consists of split-protein strategies and a selection of biosensors using 
cleavable FRET substrates. The advantages and disadvantages of each method will be discussed 
in detail in the following subsections. 
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Figure 2: Genetically encoded biosensor mechanisms  
A) Schematic of single-fluorophore biosensor mechanism. The fluorophore remains non-fluorescent 
when the two binding elements (blue semicircles) are in the open form and on binding of the analyte 
(red) the two elements undergo a conformational change which renders the FP fluorescent (Adapted 
from Ibraheem and Campbell, 2010)). B) Schematic of FRET-based biosensor mechanism. In the 
unbound state the fluorophores are further apart resulting in lower FRET and, once the binding element 
undergoes conformational changes (upon binding of the analyte), the fluorophores are brought closer 
together resulting in higher FRET (Adapted from McCombs and Palmer, 2008)). C) Schematic 
representation of the split protein mechanism “Bimolecular Fluorescence Complementation” where the 
interactions of two proteins (red and blue) bring together the two non-fluorescent protein fragments 
that refold and become fluorescent (Adapted from Ibraheem and Campbell, 2010). 
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2.2.1 Reversible Biosensors 
2.2.1.1 Single-Fluorophore biosensors  
Biosensors that employ a single fluorophore take advantage of either the fluorophores 
photophysical qualities or utilise circular-permuted fluorescent proteins (cpFPs) that typically 
results in an increase in fluorescence upon sensor activation. Biosensors that take advantage of 
photophysical qualities employ FPs that are either natively susceptible or artificially developed 
for detection of a variety of molecular events, such as halide ions (Jayaraman, 2000), voltage 
(Guerrero et al., 2002), or changes in pH  (Kneen et al., 1998).  
Due to the limited ability to exploit the integral photophysical qualities of FPs, the 
majority of single-fluorophore biosensors are developed utilising circularly-permuted FPs 
(cpFPs); involving the combination of proteins responsive to the desired molecular event and a 
redesigned fluorophore possessing alternate N- and C- termini. This results in a distorted 
secondary structure that correlates biosensor conformational change with changes in 
fluorescence intensity (Figure 2A).  The advantage of this mechanism over FRET-based 
biosensors is the unrivalled dynamic range due to the low fluorescence intensity achieved in the 
absence of the analyte of interest. Furthermore, single-fluorophore biosensors have been 
developed for a significantly wider range of applications than those employing endogenous FP 
characteristics and include maltose (Marvin et al., 2011), Ins(1,3,4,5)P4 (Sakaguchi et al., 2009), 
cGMP (Nausch et al., 2008) and ATP (Berg et al., 2009) biosensors. One biosensor group 
belonging to this class, the single-fluorophore Genetically Encoded Ca2+ Indicators (GECIs), have 
been one of the most intensely researched and improved group of single-fluorophore 
biosensors. The developmental strategies undertaken for single-fluorophore GECIs will be 
elaborated on in Section 2.3.   
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2.2.1.2 Fluorescence Resonance Energy Transfer Biosensors 
In addition to single-fluorophore biosensors a number of sensors exploit FRET as a 
method for measuring an analyte of interest. Typically this type of biosensor employs two FPs 
flanking an analyte binding domain that undergoes conformational changes (upon analyte 
binding) which result in either an increase or decrease in FRET (Figure 2B). The two FPs act as a 
“donor” and an “acceptor” FP whereby an excited state fluorophore, the donor, transfers its 
energy to an acceptor FP via non-radiative energy transmission that in turn reaches an excited 
state (Forster, 1946). In essence, when applying donor excitation the recording of emission 
from both the donor and acceptor one can document the FRET ratio changes that correspond 
to the analyte binding.  
The ratiometric nature of FRET-based biosensors confers several advantages over single-
fluorophore biosensors. For example, when developing FRET-based biosensors the FRET-
efficiency parameters can be taken into account to assist further rational design approaches. 
The first parameter, the “Spectral Overlap Integral”, describes the overlap between donor 
emission and acceptor absorption, an essential consideration when selecting a FRET-pair. 
However, it is worth noting that despite many efforts to develop further red shifted FRET-pairs 
most FRET biosensors still utilise cyan (CFP) and yellow (YFP) fluorescent protein variants 
(Figure 3A) (Piston and Kremers, 2007). The second parameter, “Förster Radius”, dictates that 
energy transfer can only occur under conditions of close proximity (10-60 Å), a fact that must 
be taken into account when considering selection of the analyte binding domain. The final 
parameter, the “Orientation Factor”, describes the orientation of the dipole moments of the 
donor and acceptor fluorophore. Whilst this orientation factor is largely irrelevant when 
considering small synthetic dyes, such as the “Alexa” dyes (Roy et al., 2008), it becomes highly 
relevant when considering biosensors with a FRET-based mechanism that contains 40 Å FPs. 
Whilst this is not a directly quantifiable factor for biosensor design (without the crystal 
structure of the proposed biosensor) it provides knowledge to improve biosensor performance 
through understanding the biophysical principles of FRET , for example, by the introduction of 
amino acids that rigidly shift the orientation or by the incorporation of cpFP donor or acceptor 
variants. An additional highly advantageous feature of FRET biosensors became apparent with 
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the application of FRET-biosensors in vivo. When using FRET-based biosensors the dual-channel 
ratiometric readout is less prone to misrepresentative recordings that can occur with single 
readout sensors due to motion artefacts, inconsistent labelling concentrations and variations in 
illumination or recording signals. 
FRET-based biosensors can utilise a number of mechanisms such as conformational-
dependent FRET change (Figure 3B) and protein-protein interaction dependent FRET that have 
been used to generate a host of FRET-based biosensors for the detection of many events 
including voltage (Akemann et al., 2010), cGMP (Niino et al., 2010), and ICAP (Friedrich et al., 
2010). Similar to the single-fluorophore biosensors one of the most engineered biosensor 
groups in the FRET-based class belongs to the GECI category, and will be discussed in detail in 
Section 2.3.  
 
 
Figure 3: Spectral overlap of FRET-pair CFP/YFP and an example of FRET  
A) Excitation (dashed) and emission (solid) spectra of the most common FP FRET pair; CFP (blue) and YFP 
(yellow). The area shaded in red illustrates the spectral overlap between CFP emission and YFP 
excitation. B) Emission spectra of the Genetically Encoded Ca2+ Indicator “TN-XXL” using CFP excitation 
in a Ca2+-free solution (black) and after 1mM CaCl2 (red) is added.  
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2.2.2 Irreversible Biosensors 
2.2.2.1 Split Protein Interactions 
Split protein strategies are a diverse group of genetically encoded tools that are based 
on the fusion of two binding partners to rationally designed protein fragments that regain 
function once the two binding partners interact to form heterodimers. Whilst the field of split 
proteins is orientated towards the understanding of protein interactions, the biosensor 
applications are not to be dismissed and indeed several significant attempts have been 
undertaken. The ability to regain protein function upon recombination of two complementary 
protein fragments was first demonstrated with bovine pancreatic ribonuclease (RNase) by 
splitting the protein into the N-terminal peptide and the rest of the molecule. These two 
fragments were shown to subsequently regain enzymatic activity upon mixing the two solutions 
(Richards, 1958). However, the ground-breaking step for the split protein field came when it 
was discovered that ubiquitin could be split and reconstituted in living cells (S.cerevisiae) by the 
association of two naturally dimerising proteins (Johnsson and Varshavsky, 1994). In the 
proceeding decades there have been several other proteins identified that can form functional 
complexes (Figure 4). In principle split protein methods can be divided into two categories; split 
proteases such as β-galactosidase (Rossi et al., 1997), dihydrofolate reductase (Pelletier et al., 
1998), and Tobacco Etch Virus (TEV) protease (Wehr et al., 2006) or proteins that result in 
increased bioluminescence or fluorescence; such as firefly luciferase (Paulmurugan et al., 2002), 
renilla luciferase (Paulmurugan and Gambhir, 2003), and GFP (Ghosh et al., 2000). 
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Figure 4: Split proteins used for protein-protein interaction studies 
Structures of proteins used for the investigation of protein-protein interactions. The separate fragments 
are indicated in red and green. The overlap between fragments is indicated in orange (Kerppola, 2008).  
 
2.2.2.2 Bimolecular Fluorescence Complementation  
Despite several split-protein strategies being developed Bimolecular Fluorescence 
Complementation has emerged as the most frequently used strategy to date. The formation of 
fluorescent FPs is achieved via the recombination of non-fluorescent FP fragments that are 
brought into close proximity via protein pairs that form heterodimers (Figure 2C). Since its 
initial demonstration, the extensive research by Tom Kerppola has served to secure FPs as the 
leading split-protein method available. Two studies published in quick succession demonstrated 
that the complementation system can not only be used to study the subcellular co-localisation 
of interacting proteins (Hu et al., 2002) but also that different FPs can be split at different 
locations (at amino acid 155 and 173 positions) and recombined together or in combination 
resulting  in FP chimeras (Hu and Kerppola, 2003). A pallet of blue to yellow FP combinations 
were developed using the dimerising proteins bJun and bFos (Patel et al., 1994) which has been 
used in a variety of organisms to study protein interactions. This selection has been further 
expanded to include red FPs such as: mRFP (Jach et al., 2006), mCherry (Fan et al., 2008), 
TagRFP (Qin et al., 2009) and mKate (Chu et al., 2009). Methodological adaptations of FP 
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complementation have further been used in structural biology (Song and Wilmanns, 2008), 
signalling networks (Rose et al., 2010) and high throughput screening (Gehl et al., 2009). 
In recent years, several complementation-based biosensors have emerged that respond 
to extracellular application of agonists when expressed in cells. The first of these, based on a 
split-EGFP architecture, used EF-hands I and II of calbindin D9k that dimerised with extracellular 
Ca2+ application (Chen et al., 2009). The poor performance of the sensor yield a maximal 
increase of 30%, however, the half-life of complementation (t1/2) was reached within minutes 
contradicting the previously held belief that t1/2 was approximately one hour (Kerppola, 2008). 
A more detailed study by Robida and Kerppola used the rapamycin-induced dimerisation of the 
FK506 binding protein (FKBP) and the FKBP-rapamycin binding domain (FRB) (Chiu et al., 1994) 
in combination with fragments of the yellow FPs “YFP” and “Venus” (and the cyan FP “CFP” as a 
transfection marker). Using Fluorescence-Activated Cell Sorting (FACS) they identified four key 
points regarding the use of complementation. These results demonstrated that fluorescence 
complementation was detectable in 10 min after rapamycin addition (longer than reported by 
Chen et al. 2009) and possessed a t1/2 of four hours that was significantly longer than previously 
thought. In combination these two observations indicated that any kinetic study aimed at the 
determination of the rate of complementation can only determine the rate for a particular set 
of dimerising proteins and cannot be generalised to the whole methodology. Furthermore, it 
was confirmed that the N-terminal fragment has a greater effect on complementation 
fluorescence intensity and in doing so identified two complementation pairs that can be used 
for different applications. Use of YN and YC (YN: YFP 1-155, YC: 156-238) was recommended 
when minimal spontaneous background fluorescence was desired, and VyN (Venus 1-155) 
when background fluorescence is not a factor of concern and maximal fluorescence intensity is 
desired. Finally also it was also observed that facilitation of protein refolding at 30 oC is 
enhanced in comparison to physiological temperatures (37 oC) but unexpectedly the ratio of 
induced versus non-induced complementation is higher at 37 oC due to the reduced 
spontaneous association of FP fragments.  
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The most recent complementation biosensor by McLachlan and colleagues was 
generated to detect Estrogenic Compounds, with the potential use for high-throughput 
screening (McLachlan et al., 2011). Using complementary fragments of Venus (VN154, VN155) 
six biosensors were generated with varying length of the oestrogen receptor alpha (ERα). The 
importance of this work lies in the unique architecture of the biosensor; rather than using two 
separate proteins that dimerise spontaneously or under induction they use the ERα domain 
flanked by the complementary Venus fragments that rely on conformational changes for 
complementation to occur. The biosensors featured here demonstrated not only the variability 
of responses elicited using Bimolecular Fluorescence Complementation in designs containing 
similar architectures but also counter intuitively demonstrated that despite the close proximity 
of the fragments spontaneous complementation can be avoided by certain orientations of the 
intervening protein.  
 
2.2.2.3 Cleavable FRET substrates  
Despite the majority of FRET-based biosensors being reversible there are several 
biosensors that consist of cleavable FRET substrates for monitoring endogenous protease 
behaviour. Typically these are not directly responsive to changes in intracellular environments 
but rather are responsive as the secondary effect to protease activation. As the substrate site 
has to be identified for the protease under investigation this category does not consist of a 
significant number of members.  Despite this, members include biosensors directed towards 
Type 1 Matrix Metalloproteinase (MT1-MMP) (Ouyang et al., 2008), Caspase-3 (Xu et al., 1998), 
and Calpain 1 (Vanderklish et al., 2000). The elegant characteristic of this FRET application lies 
in the concept that biosensors can be developed to simultaneously respond to more than one 
desired element. This feature began with the generation of a dual-Caspase FRET biosensor (Wu 
et al., 2006). Developed using three FPs that form two FRET-pairs Wu et al. were able to 
generate a biosensor that responded to not only Caspase-3 but also Caspase-6 via the insertion 
of a cleavage motif for Caspase-3 between CFP and YFP and a cleavage motif for Caspase-6 
between the YFP and mRFP to yield a CFP-c3-YFP-c6-mRFP biosensor. An alternative dual-
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protease strategy was developed for investigating two proteases crucial in the role of cancer 
invasion and metastasis. Incorporating four FPs, tethered via a transmembrane domain, the 
biosensor employed one FRET-pair that could be cleaved by the Metalloproteinase MT1-MMP 
and another for cleavage by the proto-oncogene tyrosine-protein kinase Src (Ouyang et al., 
2010). The first FRET pair, located on the outer surface of the plasma membrane, used a 
mOrange2 and mCherry pair to flank the cleavage site of MT1-MMP, whereas on the inner 
membrane an ECFP/Citrine combination were used for detection of Src.  
 
2.3 Genetically Encoded Ca2+ Indicators  
The largest biosensor group, the “Genetically encoded Ca2+ Indicators” (GECIs), were 
designed to monitor neuronal Ca2+ transients and serve as the foremost example of rational 
design of genetically encoded biosensors. Principally all GECIs employ very similar elements, 
one or two FPs and a Ca2+-binding element that either undergoes conformational changes or 
binds to target peptides. Of particular interest are the design and evolution strategies 
employed to generate improved GECI biosensors. Outlined below is the fundamental structural 
unit common to all GECIs, the EF-hand, and elaboration of the strategies undertaken for GECI 
engineering.  
 
2.3.1 The canonical EF-hand and Ca2+ binding proteins 
 The EF-hand, first identified in parvalbumin, consists of a helix-loop-helix motif 
encoded by approximately 30 amino acids that are capable of coordinating a Calcium (Ca2+) or 
Magnesium (Mg2+) ion (Kretsinger and Nockolds, 1973). Typically EF-hands are found in pairs 
and as a result most EF-hand containing proteins possess multiples of two (typically 2, 4 or 6). 
Within the EF-hand the loop region gives rise to the ion coordination space via negatively 
charged amino acids and the most typical form, the canonical EF-hand, exhibits a central nine 
amino acid binding loop with 3 amino acids extending into the following helix. These chelating 
residues are identified by two methods based on; i) the linear position (Figure 5B) and ii) the 
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tertiary geometry imposed by their alignment on the axes of a pentagonal bipyramid (Figure 
5A) (Gifford et al., 2007). The twelve amino acid sequence coordinates the metal ion via seven 
coordinating ligands relating to six amino acids. Of particular significance are the highly 
conserved N/D residues located at position 1, 3, and 5  that form the coordination positions +X, 
+Y, +Z respectively. Additionally, the most conserved amino acid, glutamic acid, at position 12 
acts as the –Z coordination amino acid that provides two chelating groups as a bidentate side 
chain. Whilst chelating groups are formed directly from these amino acids the –Y and –X 
chelating groups (position 7 and 9 respectively) are formed from the amino acid carbonyl group 
(-Y) either directly or through a bridged water molecule (-X), and thus account for the lack of 
conserved amino acids between different EF-hands. Upon Ca2+ binding the EF-hands undergo a 
structural rearrangement from almost parallel helices of each EF-hand in the “apo” (unbound 
state) to perpendicular helices in the saturated (bound state) that exposes a methionine-rich 
hydrophobic surface which is the basis for target recognition (Gifford et al., 2007). As EF-hands 
usually occur in pairs the Ca2+-binding is positively cooperative whereby Ca2+ binding to one EF-
hand presents a positive structural effect on the paired hand, thus facilitating Ca2+ binding to 
this hand. This paired function of EF-hands does not extend to other pairs present in the 
protein and as a consequence EF-hand pairs often display independent binding properties and 
biological function (Jurado et al., 1999).  
 The ubiquitously expressed Calmodulin (CaM) and the skeletal/cardiac muscle 
restricted Troponin C (TnC) belong to a family of highly homologous EF-hand proteins with a 
70% primary sequence homology (da Silva et al., 2002). Both proteins contain four EF-hands (I 
to IV) that comprise the N-lobe and C-lobe structures (Figure 5C) that are described as retaining 
a dumbbell structure due to the central flexible linker that separates the two binding pairs. 
During this transition from the apo to the saturated state the binding of Ca2+ occurs in a specific 
order based on the affinity of the EF-hands for Ca2+. Due to the paired occurrence of EF-hands 
occur in pairs the order of Ca2+ binding exhibits a lobe-to-lobe order with the pattern of binding 
being EF-Hand  III – IV – I – II. This corresponds to the Ca2+ binding first to the C-lobe and 
subsequently to the N-lobe (Gilli et al., 1998).  Upon Ca2+ binding to the higher-affinity C-lobe 
the CaM or TnC interacts with the N-terminal of the target peptide (Calmodulin Binding 
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Peptides (CBPs) or Troponin I (TnI) respectively), after which the N-lobe of CaM or TnC binds to 
the C-terminal of this peptide (Figure 5D) (Tripet et al., 2003; Yamniuk and Vogel, 2004). 
 
Figure 5: Ca2+ binding to the EF-hand and the structure of Calmodulin (CaM)  
A) Pentagonal bipyramid Ca2+ coordination geometry of the canonical EF-hand. B) Consensus sequence 
for the canonical EF-hand (Adapted from Bertini et al., 2003). C) Crystal structure of CaM (green) with 
the EF-hands (blue) bound to Ca2+ (red).PDB: 3CLN. D) Crystal structure of GCaMP2, demonstrating how 
CaM (green) wraps around the CBP M13 (purple) in the Ca2+ bound state. (NB: only 3 Ca2+ ions (red) are 
represented in this PDB file; grey: EGFP). PDB: 3EK4. 
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2.3.2 Rational design of GECIs 
2.3.2.1 Single-Fluorophore GECIs 
The single-fluorophore GECIs (or circular-permuted FP GECIs; cpGECIs) can be largely 
divided into three groups: the Camgaroos, Pericams, and GCaMPs, based on their architectural 
design (Figure 6A). The original design demonstrated by Baird et al. proved that despite the 
rigidity of the FP structure a functional FP could be produced when the N- and C- termini were 
changed (Baird et al., 1999). Furthermore, it was demonstrated that the incorporation of 
Xenopus Calmodulin (XCaM) into a circular-permuted Yellow Fluorescent Protein (cpYFP) 
exhibited a Ca2+-dependent fluorescence modulation via the conformational change of XCaM 
(upon Ca2+ binding) leading to a preferred deprotonated form of the chromophore. Despite the 
initial cpGECI (Camgaroo-1) being later improved by the replacement of YFP with the less 
environmentally-sensitive FP “Citrine” (Griesbeck et al., 2001), to yield Camgaroo-2, the 
dissociation constant (Kd) for Ca
2+ did not improve significantly (from 7µM to 5.3 µM), 
consequently limiting the use of this GECI group.  
A significant improvement in the Ca2+ affinity of the single-fluorophore GECIs was 
performed through the development of the Pericam group that exploited the same cp-Y145 
variant of YFP as Camgaroo-1 but utilised the alternative architecture of sandwiching the cpYFP 
between the Calmodulin Binding Peptide (CBP) “M13” and the XCaM (E104Q). By eliciting Ca2+-
induced interactions of CaM and M13 it was demonstrated that the novel biosensor group 
possessed a Kd range between 0.2 µM -1.7 µM that enabled the detection of neuronal Ca
2+ 
transients (Nagai et al., 2001).  
In a parallel development GCaMP was generated utilising the same architecture as the 
Pericam with the substitution of YFP for GFP. Furthermore, the design of this GECI differed from 
that of Pericam due to the application of wild-type (wt) CaM (derived from rat) and the M13 
peptide as flanking proteins surrounding a cpGFP that displayed an apparent Kd of 235 nM 
(Nakai et al., 2001).  By the incorporation of several mutations within the GFP, namely V163A 
and S175G to improve temperature stability and A206K to prevent dimerisation, (and two 
further random mutations: V93I, D180Y) GCaMP2 was generated that demonstrated a Kd of 150 
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nM (Tallini, 2006). Structural analysis via the crystallisation of Ca2+-bound and Ca2+-unbound 
states (Wang et al., 2008) and subsequent biophysical analysis (Akerboom et al., 2009) revealed 
a solvent pocket that formed the basis for structure-guided mutagenesis (and semi-rational 
library screening)  leading to the successful production of GCaMP3. Two GFP mutations (M153K 
and T203V) and one CaM mutation (N60D) in GCaMP2 yielded a 3 -fold increase in dynamic 
range and increased the affinity for Ca2+ by 1.3 -fold (Tian et al., 2009).  
 
 
Figure 6: Summary of GECI architectures  
Schematic representation of A) single-fluorophore GECI and B) FRET-based GECI architectures (Adapted 
from Mank and Griesbeck, 2008). 
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2.3.2.2 FRET-based GECIs 
Comparable to the single-fluorophore GECIs the FRET-based GECIs have also been the 
subject of substantial genetic engineering to improve the functionality in order to resolve single 
action potentials in vivo (Figure 6B). This GECI architecture consists of two groups: i) the 
Cameleons and ii) the Troponin based group.  
The Cameleons utilise the CaM/M13 interaction pair (similar to that of the GCaMPs) 
that are sandwiched between ECFP and EYFP (Miyawaki et al., 1997). Once CaM interacts with 
M13 a conformational change occurs that brings the two fluorophores into close proximity and 
results in increased FRET.  Since the initial “Yellow Cameleon-2” several attempts to improve 
the sensor by mutating the CaM domain have been proven to be unsuccessful. However, 
significant improvements have been achieved by focusing on optimising the YFP component, in 
particular the substitution of EYFP with cpVenus (Nagai et al., 2002). The largest dynamic range 
has been demonstrated by YC3.6 that incorporates a cp173Venus acceptor FP (Nagai et al., 
2004). Under this strategy this group boasted a range of Ca2+ affinities from 50-250 nM; yet cell 
transfection saw a substantial reduction in biosensor performance, most likely attributable to 
the interaction of CaM with the ubiquitously expressed cellular CaM and CBPs. Consequently, in 
order to reduce this “endogenous interference” one particular approach described in Palmer et 
al. used computational remodelling to develop a bump-and-lock redesigned M13/CaM 
interface and resulted in the D3cpv (Design 3 cpVenus). With an affinity of 600 nM this was not 
the most affine of the yellow cameleon series yet cellular performance demonstrated a 5 -fold 
increase in dynamic range (Palmer et al., 2006) that enabled the detection of single action 
potentials firing at a rate of under 1 Hz (Wallace et al., 2008). More recently, in contrast to the 
previously held belief that restriction of rotational freedom is beneficial to biosensor function, 
the addition of poly-glycine linkers improved the Ca2+ affinity of YC 2.6 to yield the Cameleon-
Nano group with an affinity range of 15 – 140 nM (Horikawa et al., 2010). 
Another strategy employed by Oliver Griesbeck utilised an alternative Ca2+-binding 
motif, Troponin C (TnC), that possessed a very similar structure to Calmodulin, however, unlike 
Calmodulin it is not ubiquitously expressed in all cell types but restricted to skeletal and cardiac 
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muscle (Parmacek et al., 1990). Sandwiched between CFP and Citrine the activity of this 
biosensor relies on the conformational rearrangement of TnC that, when bound to Ca2+, results 
in increased FRET. The first indicator denoted TN-L15 (owing to the truncation at L15) 
possessed a Ca2+ affinity Kd of 710nM (Heim and Griesbeck, 2004) that enabled the generation 
of the first transgenic mouse line expressing a GECI without inhibited biosensor performance 
(Heim et al., 2007). The disadvantage of TN-L15, the relatively high Mg2+ sensitivity, became the 
inspiration for further development that resulted in the generation of TN-XL that possessed 
several mutations aimed specifically at reducing the magnesium sensitivity (N109D, D111N, 
N145D, and D147N of the TnC C-lobe). Engineering this high speed sensor came at the sacrifice 
of Ca2+ affinity (Kd: 2200 nM) that prevented the observation of low Ca
2+ concentration changes 
associated with single action potentials (Mank et al., 2006). To circumvent this low affinity the 
domain structure was modified; the N-lobe (EF-hands I and II) was removed and the C-lobe was 
doubled to give a structure of EF-hand III, IV, III, IV. With an additional reversal of the N145D 
and D147N mutations TN-XXL was generated with a Kd value of 800 nM (Mank et al., 2008).  
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2.4 Research Objective 
In order to develop a functional genetically encoded Integrator several design strategies 
were considered and implementation of each will be discussed in detail in the following 
subsections. Whilst each design possessed theoretical merit the physical limitations generally 
encountered when developing new biosensors dictated the requirement for a multi-strategy 
approach. The approaches considered were the following; i) application of a Ca2+-dependent 
protease that cleaves a FRET substrate, ii) the generation of an artificial Ca2+-dependent 
protease that cleaves a FRET substrate, and iii) a Bimolecular Fluorescence Complementation 
split protein approach that involves the Ca2+-induced formation of a fluorescent protein.   
The first stage of Integrator development focused on the establishment of an in vitro 
platform. Subsequently, biosensor optimisation in vitro took place in order to maximise 
Integrator performance. In tandem, a stimulation method was established in cultured 
dissociated hippocampal neurons to reliably induce calcium transients over the course of 
several hours. Once completed, a combination of in vitro refinement and cell culture-based 
evaluation was undertaken until the Integrator exhibits significant performance in the cell 
based assay. Finally, a mechanism to induce Integrator expression was introduced and 
evaluated to enable temporal control over Integrator expression that is required for future in 
vivo use.  
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2.5 Integrator design approaches 
2.5.1 Approach 1: Ca2+-dependent protease FRET Integrator 
Conceptually one of the simplest Integrator architectures involved a FRET-pair that 
flanks a protease substrate site cleaved by a Ca2+-dependent protease (Figure 7). The Ca2+-
dependent protease selected for this approach, µ-Calpain, was chosen due to its high calcium 
affinity; with a dissociation constant (Kd) of 10-50 µM (Dutt et al., 2002). µ-Calpain is a 
heterodimeric Ca2+-dependent cysteine protease ubiquitously expressed in mammalian tissue 
and is comprised of two subunits, the large CAPN1 (80 kDa) and the small CAPNS1 (30 kDa) 
subunit. Structurally, CAPN1 consists of four domains; I and II comprise the protease core with 
the active site residues, domain III consists of an unknown function, and domain IV contains 5 
EF-hand motifs that are responsible for binding Ca2+. For protease function CAPN1 requires 
heterodimerisation with the small subunit CAPNS1 that consists of two domains, of which 
domain VI possesses an additional 5 EF-hands (Saez et al., 2006). Although CAPN1 domain III 
and CAPNS1 domain V appear to have no clear structure, these domains have been proposed to 
be important in cell biology applications (Larsen et al., 2004). Upon Ca2+ binding to domains IV 
and VI the heterodimer undergoes conformational changes that increase the 
accessibility/reactivity of the active site leading to autolysis that results  in two proteolytic 
subunits, a 76 -78 kDa subunit and an 18 kDa subunit (Lee et al., 2007).  
Development of a µ-Calpain Reporter (ECFP/EYFP FRET-pair flanking the µ-Calpain 
substrate) from α-Spectrin by Vanderklish et al demonstrated a FRET reduction in cells when 
Ca2+ transients were elicited by glutamatergic agonists (Vanderklish et al., 2000).  However, 
ensuing research brought these findings into doubt by the observation that the FRET Reporter 
was bound by µ-Calpain but resists cleavage (Takatsuka et al., 2005). Therefore the approach 
taken here was the in vitro development of a µ-Calpain variant that can become proteolytically 
active by lower Ca2+ concentrations (compared to the original) for the development of a FRET-
based Integrator.  
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Figure 7: Schematic illustrating proposed mechanism for µ-Calpain Integrator 
Upon Ca2+ binding to the µ-Calpain protease (P) autolysis occurs whereby the active site can bind to the 
substrate site (purple) located in-between enhanced CFP (ECFP) and the YFP variant “Citrine”. Once 
cleaved the FRET pair exhibits a FRET reduction, i.e. reduced Citrine emission and increased ECFP 
emission upon ECFP excitation.  
 
2.5.2 Approach 2: Artificial Ca2+-dependent protease FRET Integrator 
The second Integrator approach explored involved two strategies for the generation of 
an artificially Ca2+-dependent protease that cleaves a FRET reporter. The first strategy employed 
the structural rearrangement of a Ca2+-binding element (upon Ca2+ binding) in order to induce 
conformational changes of an inactive protease that yields a recovery of proteolytic function. 
The second strategy made use of a split protein architecture whereby two inactive fragments of 
a protease are brought together in a Ca2+-dependent manner. These two fragments 
subsequently refold and become proteolytically active.  
For both approaches the NIa protease from the Tobacco Etch Virus, the TEV protease, 
was selected for two primary reasons; namely the lack of TEV protease/substrate homologs in 
mammalian cells, and the previously demonstrated split protein application. With a structure 
similar to serine proteases (such as chymotrypsin and trypsin) the TEV protease is widely used 
in biotechnology for the endoproteolytic removal of affinity tags due to its substrate sequence 
specificity (Zhdanov et al., 2003).  
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2.5.2.1 Conformation-dependent Protease Integrator 
For this strategy the Troponin C (TnC) EF-Hands III and IV (C-lobe) were chosen to be 
inserted into the TEV protease primarily due to the absence of endogenous TnC or TnC-
interacting elements in nervous tissue. In addition, the C-lobe was chosen as this displays the 
largest conformational change to Ca2+ (Mank et al., 2008) whilst maintaining a relatively small 
size to maximise the likelihood of regaining proteolytic function upon Ca2+ binding. The 
proposed mechanism for this strategy employs a proteolytically-inactive TEV protease with an 
inserted TnC EF III+IV that undergoes conformational rearrangement upon Ca2+ binding to the 
TnC rendering a proteolytically active TEV protease. Once this occurs the TEV protease would 
cleave a TEV-substrate FRET Reporter (TS-FRET; ECFP- ENLYFQGS-Citrine), thus resulting in a 
reduction in the FRET ratio (Figure 8).  
 
Figure 8: Schematic illustrating mechanism of conformation-induced protease activation 
Upon Ca2+ binding the Troponin-C EF-Hands III and IV undergo a conformational change that renders the 
previously inactive TEV protease active whereby it binds to and cleaves a FRET Reporter that consists of 
CFP (ECFP) and Citrine flanking a TEV restriction site (TS-FRET).   
 
2.5.2.2 Split TEV Integrator  
The second strategy considered for the generation of an artificial Ca2+-dependent 
protease is based on the fusion of split-TEV fragments to Ca2+-dependent interacting proteins 
that could be used to restore protease activity in a Ca2+-dependent manner (Figure 9). In order 
to apply a split-TEV strategy for the Integrator the CaM and M13 peptide were chosen from the 
D3cpv FRET GECI due to the computationally redesigned ΔCaM (F19L, V35A, M36L) and ΔM13 
(K5Q, N7T, F8G, I9H, S12R, A14F, N15G, F17A). This redesigned interaction interface, the 
“bump-and-lock” interface, possesses minimal wild-type CaM (wtCaM) interference (Palmer et 
al., 2006).  
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Figure 9: Schematic for split-TEV strategy.  
CaM and M13 fused to N-TEV (TN; 1-118) and C-TEV (TC; 119-242) undergo a Ca2+ (red) dependent 
interaction that bring the two fragments of TEV into close proximity whereby they refold and form an 
active protease. Once active, the TEV protease can cleave the TS-FRET Reporter.   
 
2.5.3 Approach 3: Bimolecular Fluorescence Complementation Integrator 
In a similar approach to the split-TEV strategy, ΔCaM and ΔM13 can be fused to two 
fragments of a FP that would enable a Ca2+-dependent recombination of two non-fluorescent 
fragments resulting in the recombination and recovery of FP fluorescence (Figure 10). Unlike 
the split-TEV approach this FP recombination concept has been established in vitro using the 
heterodimerising pair bJun and bFos (Hu et al., 2002). Application of the Bimolecular 
Fluorescence Complementation architecture confers one particular advantage over other split 
protein strategies, namely, due to the signal output (in this case the YFP variant “Citrine”) being 
incorporated into the split-protein interaction the requirement for an additional FRET Reporter 
becomes redundant.  
 
Figure 10: Schematic of Complementation Integrator.  
Calmodulin (CaM) and the M13 Calmodulin-binding peptide (CBP) interact in a Ca2+-dependent manner 
bringing two fragments of the YFP variant “Citrine”, the N- (YN) and C- (YC) fragments, into close 
proximity where they refold and form a fluorescent protein.  
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3 Materials and Methods 
3.1 Molecular Biology 
3.1.1 Polymerase Chain Reaction 
Developed in 1983 by Kary Mullis, Polymerase chain reaction (PCR) is a commonly used 
technique in molecular biology to amplify a distinct strand of DNA. This technique takes 
advantage of a thermally stable DNA polymerase with a bacterial or archeal origin. The most 
commonly used polymerase Taq (Thermus aquaticus) was the first thermostable polymerase 
used for PCR, however, since its discovery several other polymerases, for example Vent 
(Thermococcus litoralis) and Pfu (Pyrococcus furiosus), offer improved features such as 
increased thermostability and significantly decreased error rate of replication. Additional 
bioengineering strategies, for example Agilent’s “Herculase II”, further increase the affinity and 
subsequently reduced the PCR cycling times by fusing a Pfu-based DNA polymerase with a high 
affinity double-stranded DNA binding domain. Therefore, Herculase II was chosen for PCR 
reactions due to its enhanced reliability and high product yield (Table 1).  
Table 1: PCR Reaction (<1.5kb) 
Component Volume (µl) 
Forward Primer (100pM) 0.5 – 1 
Reverse Primer (100pM) 0.5 – 1 
Template DNA (100ng) 0.5 – 1 
5xHerculase Buffer 10 
DMSO (optional) 5 
dNTPs (12.5mM) 1 
Herculase II Polymerase 1 
H2O 30-37.5 
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All reaction components were added on ice and the PCR was initiated in a DYADTM DNA 
Engine (MJ Research) at 95oC to reduce PCR primer dimerization and to increase specificity 
(Table 2). The addition of DMSO increases the yield of PCR product and was included when 
template DNA concentration was under 100 ng. However, in general DMSO was avoided due to 
the addition of DMSO resulting in an increased replication error rate.   
Table 2: PCR Cycle 
Cycle Temperature <1kb 1-2kb Step 
1. 95oC 2min 20sec  
2. 95oC 20 sec Denaturing 
3. 55oC 20 sec Annealing 
4. 72oC 30 sec 1.0  min Elongation 
5. Repeat from 2. 29  
6. 72oC 3.0 min 
7. 15oC Forever 
Total Time  1hr 
18min 
1hr 
32min 
 
 
3.1.2 Site-directed mutagenesis 
In addition to the use of PCR for the amplification of a desired fragment of DNA it can 
also be used for site-directed base substitutions. Mutations are introduced by substituting 
certain nucleotide bases in the primer sequence with the preferred sequence. To enable this, 
PCR primers are designed with the desired nucleotide substitutions flanked by at least 42 bases 
(14 codons) evenly divided between the N- and C- terminus.  
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Table 3: Site-Directed Mutagenesis Reaction 
Component Mutagenesis Reaction 
Volume (µl) 
Control Reaction 
Volume (µl) 
Forward Primer (10pM) 1 
Reverse Primer (10pM) 1 
Template DNA (100ng) 1 
5xHerculase Buffer 10 
dNTPs (12.5mM) 1 
Herculase II Polymerase 0.5 - 
H2O 35.5 36 
 
Table 4: Site-Directed Mutagenesis Cycle 
Cycle Temperature Duration Step 
1. 95oC 30 sec  
2. 95oC 30 sec Denaturing 
3. 57oC 1.0 min Annealing 
4. 72oC 6.0 min Elongation 
5. Repeat from 2. 15  
7. 15oC Forever 
Total Time  2hr 21min 
 
The site-directed mutagenesis protocol (Table 3) was performed for one or two 
mutation sites in parallel (one forward and one reverse primer for each mutation site). Upon 
site-directed mutagenesis PCR (Table 4) completion the template DNA was digested via 
addition of DpnI endonuclease (target sequence: Gm6ATC). As template DNA isolated from 
most E.coli strains is dam methylated it is susceptible to DpnI digestion which is specific for 
methylated and hemimethylated DNA (Table 5). Subsequent incubation of 1 hour was followed 
by transformation into XL-1 Blue competent cells, whereby 1 µl of the DpnI digested solution 
was used.  
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Table 5: DpnI Digest 
Component Mutagenesis Reaction  
(Herculase II PCR) 
Volume (µl) 
Control Reaction 
(No Herculase II) 
Volume (µl) 
PCR Product 20 
DpnI 1 
Incubation 4 Hours at 37oC 
 
3.1.3 Restriction of DNA 
Restriction recognition sites are short palindromic sequences, typically 6 nucleotides in 
length that are recognised by restriction-site specific restriction endonucleases. These 
endonucleases cut the sequence between two nucleotides resulting in two overhanging “sticky 
ends” which are used to ligate pieces of DNA with complimentary overhangs. DNA for ligation 
was prepared using a “Preparative Digest” which employs restriction enzymes to digest 1-10 µg 
of vector (the vector backbone) or insert DNA (DNA fragment desired for insertion into the 
vector backbone) (Table 6). Additionally, DNA restrictions can also be used to determine 
whether the inserted DNA has successfully been integrated into the vector DNA, a process 
known as an “Analytical Digest”. 
 
Table 6: Restriction Digest Reaction 
Component Preparative Digest 
Volume (µl) 
Analytical Digest 
Volume (µl) 
DNA (100-1µg) 10 2 
NEB (10x) Restriction Buffer 5 2 
Bovine Serum Albumin, BSA 
(100x) 
0.5 0.2 
Restriction Enzyme #1 1 0.2 
Restriction Enzyme #2 1 0.2 
H2O 32.5 15.4 
Incubation at 37oC (hours) 16  1 
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3.1.4 Dephosphorylation of Vector DNA 
Phosphatases catalyse the removal of 5’ phosphate groups from the digested vector 
DNA preventing self-ligation and consequently improving the efficiency of “insert” DNA ligation 
into the vector. Antarctic Phosphatase was chosen for this step due to the requirement of heat-
inactivation of the phosphatase (Table 7).  
Table 7: Dephosphorylation of Vector 
Component Volume (µl) 
Vector DNA (1-10µg) 30 
NEB (10x) Antarctic 
Phosphatase Buffer 
4 
NEB Antarctic Phosphatase 1 
H2O 5 
Incubation at 37oC (hours) 1-2 
Deactivation at 70oC (min) 15 
 
3.1.5 DNA ligation 
DNA ligation can either be performed using a “blunt-end” ligation (ligates DNA without 
overhanging restriction sites) or “sticky-end” ligation (utilises digested DNA). Sticky-end ligation 
was performed due to the higher ligation yield generally obtained. In addition, DNA ligases are 
used to facilitate ligation as these catalyse the formation of phosphodiester bonds between 
juxtaposed 5’ and 3’ termini. The most commonly used ligase, isolated from bacteriophage T4, 
is the T4 DNA Ligase that exhibits optimal activity at 25 oC (Table 8). The molar ratio of vector to 
insert DNA used in this reaction was that of 1:3 to 1:5. These concentrations were estimated by 
agarose gel electrophoresis. 
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Table 8:  DNA Ligation 
Component Ligation 
Volume (µl) 
Vector Control 
Volume (µl) 
Vector DNA  1 1 
Insert DNA 3 - 
NEB Ligase Buffer (10x) 2 2 
T4 DNA Ligase  1 1 
H2O 13 16 
Incubate 3 hours at 25oC 
 
3.1.6 Preparation of chemically-competent E.coli 
4 ml LB medium, inoculated with the desired E.coli strain, was incubated without 
antibiotics overnight at 37 oC shaken at 250 rpm. 1 day cultures were added to 300 ml LB 
medium and grown to an OD600 of 0.5-0.6 before incubation for 20 min on ice. Cells were 
harvested by centrifugation at 2500 g for 20 min at 4 oC. The supernatant was discarded and 
the cells were resuspended with 60-80 ml of cooled Inoue transformation buffer. Cell 
suspension was subsequently centrifuged at 2500 g for 15 min at 4 oC and resuspended with 
20ml cooled Inoue transformation buffer supplemented with 1.5 ml DMSO. The suspension was 
incubated on ice for 10min before being aliquoted (50 μl) and stored at -80 °C.  
 
3.1.7 Preparation of electro-competent E.coli 
20ml antibiotic-free LB medium, inoculated with the desired strain of E.coli, was grown 
overnight and added to 1 l pre-warmed LB medium (37 °C). Cells were subsequently grown to 
an OD600 of 0.4- 0.5 and the culture was incubated on ice for 10 min before harvest 
(centrifugation 2500 g for 10min at 4 °C). The supernatant was discarded and cells were 
resuspended in 150 ml of 10 % Glycerol and additionally incubated on ice for 1 hour. 
Centrifugation and resuspension steps were repeated three times, each time reducing the 
volume of 10 % glycerol, from 50 to 20 to finally 0.5 ml glycerol. Electro-competent E.coli were 
aliquoted in 50 μl aliquots and stored at -80 °C until required.  
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3.1.8 Transformation of chemically-competent E.coli 
Chemically competent cells XL-1 Blue and BL21 were used for DNA replication and 
protein expression respectively. Cells were thawed on ice and transformed with 10 µl of the 
ligation mix and incubated on ice for 20min. Cells were subsequently heat-shocked for 1 min at 
42 oC before 2 min incubation on ice. Transformations using ampicillin-resistant bacteria were 
plated out on ampicillin containing LB-agar plates. Bacteria with other antibiotic resistance 
were incubated with 200 µl antibiotic-free LB-media for 1 hour at 37 oC before plating on LB-
agar plates containing the appropriate antibiotics. 
 
3.1.9 Transformation of electro-competent E.coli 
Electroporation of electrically-competent E.coli was performed when a high yield of 
transformed bacteria was desired. Cells were thawed on ice and added to a 2 ml pre-cooled 
electroporation cuvette (Peqlab) with 1-2 µl of DNA. An 1800 V electrical pulse (Equibio) was 
applied and 200 µl-1 ml SOC medium was immediately added (Invitrogen). Cells were incubated 
for 1 hour at 37 °C before subsequent plating on LB-agar plates supplemented with the 
appropriate antibiotic.  
 
3.1.10 Transposon Reaction and Screening 
Transposons are mobile prokaryotic or eukaryotic DNA sequences that can transpose 
themselves into new positions within the genome of individual cells. Since their first 
identification, over 60 years ago (McClintock, 1950), they are viewed as symbiotic as they 
contain antibiotic resistance genes that assist cell survival. In prokaryotic systems, the cell 
provides the cellular environment for element transposition (Wiegand and Reznikoff, 1992). 
The Tn class, a bacterial class of transposase, are used extensively in molecular biology as these 
single subunit transposases were subject to a triple mutation to yield hyperactive transposition 
(Hoffman and Jendrisak, 2002). These hyperactive transposases are ideal for in-vitro 
transcription studies.  In this research, the EZ-Tn5TM in-frame Linker Insertion Kit (Epicentre) 
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(Table 9) was utilised. Hereby a random sequence was inserted that can be read in any of the 
three reading frames and encodes a NotI Kanamycin resistant gene flanked by 57 bp.  
Table 9: Transposon Reaction 
Component Volume (µl) 
Target DNA  2 
EX-Tn5 Reaction Buffer (10X) 1 
EZ-Tn5 <NotI/KAN-3>  Transposon 0.8 
H2O 5.2 
EZ-Tn5 Transposase 1 
Incubate 2 hours at 37oC 
EZ-Tn5 Stop solution (10X) 1 
Incubate 10 minutes at 70oC 
 
Upon completion of the transposon reaction, 1 µl of the reaction was added to XL-1 
Blue electrocompetent cells and electroporated before transferral to agar plates with 
Kanamycin and Ampicillin antibiotics. 
 
3.1.10.1 Transposon Screening 
Due to the stop codon located at the end of the insertion fragment, bacterial colonies 
possessing the Transposon fragment could be selected for via selection of non-fluorescent 
bacterial colonies. The positive colonies were subsequently digested to remove the transposon 
before being re-streaked (Figure 11).  Once colonies were selected via mCherry fluorescence 
(after transposon removal) the location of the insertion was determined from the original 
colony (with transposon inserted) via restriction digest and subsequent agarose gel 
electrophoresis. Chosen samples were subsequently purified either with the Transposon or 
with Troponin C EF-hands III + IV inserted.  
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Figure 11: Transposon screening strategy 
Schematic of screening strategy for ΔTEV-mCherry (mCh)-pRSETB. Random insertion of transposon 
fragment yields three outcomes for Round 1 of screening; i) fluorescent cells where the transposon is 
inserted downstream of mCherry, ii) non-fluorescent cells where the transposon is inserted before 
mCherry, or iii) no colony growth where the transposon interferes with the Ampicillin resistance. Round 
2 of screening identified mCherry fluorescent colonies (with Transposon removed), after which a sample 
were selected for Troponin C (TnC) EF-hand III + IV insertion.  
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3.2 Protein Biochemistry 
3.2.1 Protein Expression 
For recombinant protein expression the cDNA of interest was cloned into the Multiple 
Cloning Site (MCS) of either pRSETB or pRSFDuet plasmid. Two features of these plasmids 
enable the successful expression and purification of the protein of interest; i) both plasmids 
carry a T7 RNA polymerase promoter that directs high-level expression in E.coli and ii) with the 
addition of a 6xHis-tag on either the N- or C- terminus the protein can be purified via affinity 
purification The plasmid, containing the cDNA of interest, was transformed into the E.coli strain 
BL21 before overnight incubation at 37 oC (200 rpm) in 5 ml of LB medium containing the 
corresponding antibiotic (50 mg/ml 1: 500). Pre-culture was used to inoculate 200 ml LB 
medium containing 1: 1000 antibiotic and incubated at 37 oC until an OD600 of 0.6 was reached. 
Protein expression was induced with 1mM Isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 3-4 
hours at 200 rpm at 25 oC. Bacterial cells containing the protein of interest were subsequently 
harvested by centrifugation (Sorvall) at 6000 g for 10 min at 4 oC and resuspended in 10 ml 
protein resuspension buffer supplemented with protease inhibitors (1 mM PMSF, 5 µg/ml 
Pepstatin and 1 µg/µl Leupeptin) In the purification of proteases the appropriate protease 
inhibitors were omitted. The resuspension was frozen at -80 oC to induce cell lysis and for 
storage. 
 
3.2.2 Protein Purification 
Cells were lysed using 1 mg of Lysozyme for 30 min on ice. Cell membranes were 
solubilized by the addition of 0.1 % Triton-X-100 detergent, 5 µg/ml DNAse and 5 µg/ml RNAse 
before the final lysis step by ultrasonification (Sonorex Ultrasonic Bath, Bandelin) for 30 min at 
4 oC. Following centrifugation at 13,000 rpm the protein extract was loaded in to 400 µl Ni-NTA 
agarose beads (Quiagen) and incubated for 2 hours at 4 oC. Gravity flow purification was 
undertaken using a polypropylene column (Quiagen). Ni-NTA beads were washed with the 
resuspension buffer containing 10 mM imidazole in order to remove weakly bound protein.  
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Recombinant proteins are then eluted by the elution buffer containing a high concentration of 
150 mM imidazole and 10 % glycerol. The protein was stored at -80 oC. 
 
3.2.3 Western Blot 
Dissociated hippocampal neurons were cultured in 12-well glass-bottom plates 
(MatTek). Cells were washed with 1x PBS before being lysed and boiled at 100 oC for 15 min. 
Protein concentration was determined using the Bradford Assay (Bio-Rad) and the absorbance 
at 595 nm was measured (TECAN plate reader, Tecan). 25 µg of protein was separated by SDS-
PAGE using 10% Separation Gels. Gels were transferred to a nitrocellulose membrane via semi-
dry blotting. Membrane was blocked for 1 hour in a non-fat milk buffer (5 % milk in 1x TBS-T) 
and subsequently incubated overnight at 4 oC in an anti-GFP primary antibody (1: 1000; 
Research Diagnostics Inc.). After six 5 min washing steps in 1x TBS-T the membrane was 
incubated with the anti-rabbit secondary antibody (1: 1000; Invitrogen) before an additional 30 
min washing period. Membrane was immersed in an ECL solution (Santa Cruz) for 1 min and 
developed using Amersham Hyperfilm (GE-Healthcare). The membrane was additionally 
washed for 30 min before incubation for 1 hour with the anti-tubulin loading control antibody 
(1: 5000; Abcam). The membrane was subsequently incubated with the anti-mouse secondary 
antibody (1: 1000; Invitrogen) and developed using the technique described above.  
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3.3 Spectroscopy 
3.3.1 Fluorescent spectra of purified proteins  
Protein concentration was determined using a Nanodrop (Peqlab) and a 0.75 µM 
concentration per protein was used for each experiment unless otherwise stated. Fluorescence 
was measured using the fluorescence spectrophotometer (Varian).  Proteins were diluted in 10 
mM MOPS buffer containing 100 mM KCl and 25 µM EGTA in order to set the Ca2+ free ion 
concentration to zero. Additionally, 1 M CaCl2 and MgCl2 stock solutions were added (1: 1000) 
for experiments requiring 1 mM CaCl2 and 1 mM MgCl2. FRET fluorescence was measured at 
excitation and emission wavelength of 432 and 450-600 nm respectively (bandwidth 5 nm). For 
complementation the fluorescence measurement was carried out at an excitation and emission 
of 500 and 510-600 nm respectively (bandwidth 5 nm).  
The following formula was used to calculate the ∆R/R for FRET changes: 
  
 
[ ]  
         
    
     
Where: 
Ratio (R) =       
       
   
 
     
     
  
RMax= Ratio of Ca
2+-bound  
RMin = Beginning Ca
2+ value at 0min 
 
The same formula was applied for calculating the change in complementation 
fluorescence; however the ratio was replaced by a single wavelength fluorescence to generate 
ΔF/F. For experiments requiring a temperature of 37 oC a H2O circulated cell holder (Varian) was 
used in conjunction with a water bath (Julabo). The peptide screen was performed using a 96-
well plate and a 2 mM CaCl2 concentration to induce detectable differences in spontaneous 
versus inducible complementation.  
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3.3.2 Spectroscopic determination of EC50 
Determination of the EC50 via Ca
2+ titrations of biosensors required two proteins; the 
YN-CaM and the CBP-YC recombinant protein. Protein concentrations were determined using a 
Nanodrop (Peqlab) and 0.75 µM were combined in a total volume of 50 µl. These were 
subsequently frozen in liquid nitrogen and stored at -80 oC. For the determination of EC50 two 
Ca2+ solutions were prepared in accordance with previous literature (Tsien and Pozzan, 1989). 
The two solutions were combined in order to give a desired concentration of free Ca2+ ions 
determined by the Maxchelator program “Webmaxc” (Table 10). Upon addition of the protein 
solution to the series of Ca2+ solutions a 4 hour incubation time was undertaken either at room 
temperature or 37 oC.  Once fluorescence was recorded the ΔF/F (or ΔR/R) values were 
normalized to the highest value before plotting the log10 values of the free Ca
2+ points using 
Origin 8.1. Determination of the EC50 values was achieved by sigmoidal fit.  
Table 10: Ca2+ Titration Solution 
Calcium Concentration at 
37oC (µM) 
Calcium Concentration at 
25oC (µM) 
10mM Ca2EGTA  
Volume (µl) 
10mM K2EGTA 
Volume (µl) 
0 0 - 950 
0.083 0.1010 375 575 
0.120 0.1394 450 500 
0.228 0.2655 600 350 
0.373 0.4337 700 250 
0.711 0.826 800 150 
1.1 1.3 850 100 
2.3 2.7 900 50 
4.0 4.6 920 30 
6.0 6.9 930 20 
11.3 12.9 940 10 
20.9 23.4 946 4 
27.2 29.8 948 2 
36.0 38.7 950 - 
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3.4 Cell Culture 
3.4.1 Preparation of dissociated hippocampal neurons 
All of the following methodology was conducted in a laminar flow hood using sterilized 
equipment and standard aseptic techniques. Primary hippocampal neurons derived from rat 
embryos were removed and cultured as previously described (Audesirk et al., 2001) . Pregnant 
female E18 Wistar rats were sacrificed using CO2 before opening of the abdomen and removal 
of the embryos. Using micro-dissection forceps and dissecting scissors the embryos were 
removed from the uterus and placed into a PBS-filled petri dish before decapitation and 
transferral of the heads to an additional PBS-filled dish. Using forceps the head was anchored to 
allow the opening of the longitudinal fissure. Once extracted, the brain was separated into the 
two hemispheres and the meninges were removed before final separation of the hippocampi 
from the adjacent tissue using a dissection microscope (Leitz). The hippocampi were then 
transferred to a 2 ml Trypsin solution (7 µM Hepes) pre-warmed to 37 oC. After five minutes 
incubation at 37 oC the hippocampi were dissociated by trituration. The triturated solution was 
then centrifuged at 2000 rcf for 2 min before the Trypsin solution was aspirated and the 
hippocampi were resuspended in 1 ml PBS with 1 % Pen/Strep. The neurons were centrifuged 
at 2000 rcf for 2 min before resuspension in 2 ml DMEM enriched with 10 % FCS and 1 % 
Pen/Strep and pre-warmed to 37 oC.  
Glass-bottom culture dishes (35mm, MatTek) or µ-Dishes (Ibidi) were incubated 
overnight with Poly-L-Lysine before being washed with 1x PBS and the addition of 2 ml DMEM 
enriched with10% FCS and 1% Pen/Strep and subsequent incubation at 37oC, 5% CO2 (Heracell, 
Thermo Scientific). Neurons were counted using a haemocytometer and plated at a density of 
200,000 cells per dish. The medium was replaced after 12 hours by Neurobasal media 
supplemented with B27 and 60 mM NaCl and were retained for up to 1 week.  
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3.4.2 Passaging immortal cell lines 
Upon reaching 80 % confluency the HEK293T cell line was washed with 1x PBS before 
addition of 2ml Trypsin and incubated for 5min at 37oC. Once cells detached 8 ml DMEM 
solution (DMEM enriched with 10% FCS and 1% Pen/Strep was added and the cells were 
triturated before seeding. For either 3.5 cm or 10 cm culture dished the seeding ration was 1:10 
triturated solution to DMEM solution.  
 
3.4.3 Transient transfection of mammalian cells 
Delivering DNA to mammalian cells can be achieved by several methods, with some 
relying on physical manipulation (e.g. electroporation), the use of chemicals (e.g. Ca2+ 
phosphate), or lipofection. Lipofection utilises liposomes carrying genetic material to merge to 
the phospholipid bilayer of the cell membrane. This method is advantageous for several 
reasons; not only does it deliver a high transfection efficiency but also exhibits low toxicity, cell 
type versatility and a high level of reproducibility. The lipofection reagent Lipofectamine 2000 
(Invitrogen) was used for transfection of both dissociated hippocampal neurons and immortal 
cell lines with the DNA of interest in the MCS of pCDNA3. For 35 mm glass-bottom culture 
dishes 7 µl of lipofectamine were incubated for 5 min with 250 µl of Opti-MEM in order to allow 
lipid vesicle formation. After vesicle formation 250 µl of Opti-MEM (with 1-3 µg DNA) were 
incubated at 25 oC for 20 min for DNA incorporation into lipid vesicles. During this time the cell 
culture dishes were prepared for transfection. For dissociated neurons this required the 
removal and storage of 500 µl conditioned media and for immortal cell lines this required a 
complete replacement of media containing antibiotics with antibiotic-free media.  500 µl of 
transfection mix was added to the plates and incubated at 37 oC with 5 % CO2 for 3 hours prior 
to the replacement of the media/transfection mix with DMEM solution or Neurobasal (60 mM 
NaCl).  
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3.5 Generation of Semliki Forest Virus 
The Semliki Forest Virus (SFV), a member of the alphavirus genus, is a positive-stranded 
RNA virus with an icosahedral capsid enveloped by a lipid bilayer that originated from the host 
cell. This dual plasmid infection system requires a helper plasmid (pSCA-Helper) that encodes 
the SFV structural proteins and the pSCA-1 plasmid yielding the coding sequence for the cDNA 
of interest and the packaging signal for the SFV.   
10 cm dishes of HEK293T cells were incubated at 37 oC with 5 % CO2 until 70 % confluent 
before transient transfection of the two plasmids. In preparation for transient transfection the 
DMEM solution was removed from the HEK293T cells before washing with 1x PBS and the 
subsequent addition of 5 ml antibiotic-free DMEM solution. 40 μg total DNA at a ratio of 3:2 
(pSCA-DNA: pSCAHelper) was added to a solution containing 50 µl Lipofectamine 2000. After a 
30 min incubation period this solution was added to 10 cm dishes and allowed to incubate at 
37oC with 5% CO2 overnight (NuAire Incubator). The next morning, after verification of 
transfection by fluorescence microscopy (Olympus), the medium was changed and cells were 
incubated for an additional 2 days. The supernatant was subsequently and cellular debris was 
removed via 10 min centrifugation at 2500 g and 4 oC. The viral particles were rescued by 
ultracentrifugation at 20,000 rpm for 90 min at 4 oC (Beckman Coulter) and the supernatant 
was completely removed (95 % by aspiration, 5 % by 10 min ultracentrifuge tube inversion). The 
virus particles were resuspended in 200µl TBS and incubated overnight at 4 oC. Specifically 
designed mutations within the glycoprotein render the virus inactive until the virus is 
proteolytically treated. This was achieved by incubation with α-chymotrypsin (1: 20 dilution) for 
45 min at room temperature before protease inactivation with aprotinin (1: 15 dilution) for 10 
min. Activated virus was aliquoted and stored at -80oC. 
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3.6 Dissociated Hippocampal neuron assays 
Neurons possess several types of voltage-gated ion channels that function in response 
to a change in the electrical potential across the neuron. In order for neurons to exhibit such 
variety in firing response (i.e. burst firing, slow wave firing) several types of voltage-gated ion 
channels exist, each with its own response profile. One type of voltage-gated ion channel is the 
voltage-dependent Ca2+ channels, a group of gated channels that are activated upon membrane 
depolarization causing a Ca2+ influx that can induce dendritic neurotransmitter release amongst 
other roles. These channels are classified according to their response to current type, and are 
categorised as L-Type, N-Type, P/Q-Type, or R-Type. Ca2+ influx via the opening of voltage-gated 
Ca2+ channels result in increased intracellular Ca2+ concentrations. 
 
3.6.1 12-well plate Electrical Field Stimulation  
Using a 12-well plate one can apply Electrical Field Stimulation for varied time durations 
and record the cumulative output from many neurons. Neurons were therefore cultured for 3-6 
days in 12-well culture plates (MatTek or Becton Dickinson) in Neurobasal (B27, 60mM NaCl). 
Transient transfection of cDNA or infection of SFV was subsequently carried out followed by 
media replacement. The lid was exchanged for a custom-built lid with 12 parallel pairs of 
platinum electrodes with 1 cm separation. This was connected to a custom built stimulator 
device and the culture plate was placed back in the 37 oC incubator. The stimulation protocol 
was initiated and wells were activated in a series of one hour steps (Figure 12) for 4 hours. The 
neurons were imaged with the iMIC Microscope (Till Photonics). For separate CYP and YFP 
imaging CFP and Citrine were imaged with an excitation wavelength of 432 nm and 505 nm 
respectively using a Dualband CFP/YFP filter; Exc1: BP 430/24, Exc2: BP 490/20. The emission 
was separated into CFP and YFP images using a Dualband CFP/YFP filter and a dichrotome dual-
emission extension inbuilt into the iMIC. For FRET imaging both YFP and CFP were imaged using 
the CFP excitation wavelength. Image recording was performed using the dual-emission 
extension followed by image analysis using ImageJ software (NIH). Statistical analysis was 
performed using a one sample t-test. 
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Figure 12: Electrical Field Stimulation of 12-well plates 
Stimulation of dissociated hippocampal neurons with 4 hour stimulation was initiated at the beginning 
of the experiment and 3, 2, 1 hour stimulations were subsequently initiated to ensure the same 
experimental end point.  
 
 
3.6.2 Electrical Field Stimulation for live-cell fluorescence microscopy 
Neurons were cultured on 35 mm culture dishes for 3-4 days before experiment 
initiation. Glass-bottom µ-dishes (Ibidi) were used for imaging at 37 oC with the addition of a 
heating chamber (Ibidi). Culture dish media was exchanged for a HEPES buffered solution and 
allowed to equilibrate to 37 oC for 5 min. Upon being placed on the imaging stage two parallel 
platinum electrodes 1 cm apart were placed in the solution and connected to a triple output DC 
power supply (Agilent) via a custom built amplifier. Stimulus protocols were modified via 
LabView connected to a waveform generator (Agilent) and upon protocol execution the 
stimulation bursts were monitored by a 30 MHz Oscilloscope (Grundig). Cells were imaged at 5 
min intervals using an iMIC as detailed in the section above and images were analysed using 
ImageJ software.  
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3.6.3 Fluo-4 AM Ca2+ dye imaging  
In order to detect neuronal activity directly once can use the visualisation of Ca2+ 
transients using synthetic Ca2+ dyes such as Fluo-4 AM (Invitrogen). For use in 35 mm glass 
bottom culture dishes (MatTek) the 50 µg Fluo-4 AM aliquots were resuspended in 50 µl DMSO 
and a final Fluo-4 concentration of 5 µM was applied for 30 min. Media replacement and a 30 
min incubation ensured de-esterification. Culture dishes were mounted on a 135 TV Axiovert 
Microscope possessing a 515 nm LED excitation wavelength. Field stimulation was applied as 
previously described and images were taken using an iXonEM+ Camera System (Andor Tech). 
Analysis was performed using ImageJ software. 
 
3.6.4 LIVE/DEAD Viability/Cytotoxicity Assay 
When performing cell stimulation experiments one vital consideration is whether the 
experimental paradigm can cause unwanted cellular toxicity leading to premature apoptosis. 
Viability assays can be used to determine the ratio of healthy to apoptotic cells via probes 
engineered to detect each condition. The LIVE/DEAD assay utilized two probes; Calcein AM and 
Ethidium Homodimer-1 (EthD-1). Live cell esterase activity converts the cell-permeant Calcein 
AM non-fluorescent probe to the fluorescent Calcein (excitation 495nm, emission 515nm). 
Contrastingly, EthD-1 cannot permeate intact membranes; however, once the membrane is 
damaged the probe can enter the nucleus where it undergoes a 40-fold enhancement in 
fluorescence (excitation 495nm, emission 635nm). The feature of fluorescence enhancement 
upon cellular interaction yields this dual-probe particularly beneficial as there is no background 
fluorescence. Upon completion of the 12-well Electrical Field Stimulation the cells were 
incubated with 1 µM Calcein and 6 µM EthD-1 in 1x PBS for 30 min before imaging Calcein 
(excitation 495nm ±15nm, emission CFP/YFP) and EthD-1 (excitation 495nm ±15nm, emission 
ET630/75nm). Cell counting was achieved using ImageJ and the percentage of cell survival was 
calculated using the following equation: 
              [ ]  
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3.7 Materials 
3.7.1 Instruments 
Instrument Name Supplier 
1103 Polychrome control Unit Till Photonics (Germany) 
135 TV Axiovert Microscope Carl Zeiss (Germany) 
30 MHz Oscilloscope Grundig (Germany) 
Arbitrary Waveform Generator (20mHz) Agilent (USA) 
Autoflow CO2 Water-Jacketed Incubator NuAire, Plymouth (USA) 
Cary 100 Scan UV-Visible  Spectrophotometer Varian (Australia) 
Cary Eclipse Fluorescence Spectrophotometer Varian (Australia) 
Cary H2O Circulated Cell Holder (Cary Eclipse) Varian (Australia 
CKX414 Inverted Microscope Olympus (Japan) 
Dissecting Microscope Leitz (Germany) 
DYADTM DNA Engine  MJ Research Inc. (USA) 
EasyjecT Prima  Equibio (Germany) 
GelDoc 2000 Videosystem BioRad (USA) 
Heracell 240 CO2 Incubator Thermo Scientific (USA) 
HT200 Heating Chamber Ibidi (Germany) 
ImageJ Image Processing Program National Institutes of Health (USA) 
iMIC Digital Microscope Till Photonics (Germany) 
iXonEM+ Camera System Andor Tech (USA) 
M205 FA Fluorescence Microscope Leica (Germany) 
MB-5 Heating Circulator Julabo (Germany) 
Nanodrop 1000 Spectrophotometer Peqlab (Germany) 
Optima LE-80K Ultracentrifuge Beckman Coulter (USA) 
Origin 8.1 Software OriginLab Corporation (USA) 
PCO- Imaging Sensicam Till Photonics (Germany) 
Polychrome V Till Photonics (Germany) 
RC-5B Refrigerated super speed centrifuge Sorvall (USA) 
Sonorex Digital Ultrasonic Bath Bandelin (Germany) 
TECAN Plate Reader (GENiosTM) Tecan (USA) 
Triple Output DC Power Supply Agilent (USA) 
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3.7.2 Consumables 
Consumable Name Supplier 
µ-Dish 35mm High Ibidi (Germany) 
2mm Electroporation Cuvettes Peqlab (Germany) 
Amersham Hyperfilm ECL GE-Healthcare (USA) 
Anti-GFP primary antibody Research Diagnostics (USA) 
Anti-Mouse secondary antibody Invitrogen (USA) 
Anti-Rabbit secondary antibody Invitrogen (USA) 
Anti-Tubulin primary antibody Abcam (USA) 
BCA Protein Assay kit Pierce (Germany) 
Bovine Serum Albumin (BSA) Sigma (USA) 
Dulbecco's modified Eagle's medium (DMEM) w/o 
Sodium Pyruvate; w/ 4500 mg/ml Glucose; w/ 
Pyridoxine-HCl 
Invitrogen (USA) 
Dulbecco's modified Eagle's medium /F12 Invitrogen (USA) 
Falcon Tissue Culture Plate, 12 Well Becton Dickinson (USA) 
Fetal Bovine Serum Gibco (USA) 
Fluo-4 AM Calcium Dye Invitrogen (USA) 
Glass Bottom 12-Well Culture Plates  
Nr. P12G-0-14-F 
MatTek Corp. (USA) 
Glass Bottom Culture Dishes 35mm,  
Nr. P35G-0-14-C 
MatTek Corp. (USA) 
Herculase II Fusion DNA Polymerase Stratagene (USA) 
His Mag Sepharose Ni GE Healthcare (UK) 
Lipofectamine 2000 Invitrogen (USA) 
LIVE/DEAD Viability/Cytotoxicity Kit Molecular Probes (USA) 
µ-Calpain (Porcine Erythrocytes) Merck (Germany) 
NeuroBasal medium Gibco (USA) 
Ni-NTA Agarose Qiagen (Germany) 
Opti-MEM I Invitrogen (USA) 
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Polypropylene Columns Qiagen (Germany) 
Pure Yield Plasmid Midiprep System Promega (USA) 
QIAquick Gel Extraction Kit Qiagen (Germany) 
QIAquick Miniprep Kit Qiagen (Germany) 
QIAquick PCR Purification Kit Qiagen (Germany) 
Restriction Enzymes New England Biolabs (USA) 
SOC medium Invitrogen (USA) 
T4-Ligase New England Biolabs (USA) 
Western Blot Luminol  Santa Cruz Biotechnology (USA) 
 
3.7.3 Buffers and Solutions 
Name Supplier 
Ca2EGTA Solution for Ca
2+ Titrations 10 mM K2CaEGTA 
1 mM MgCl2 
MOPS Buffer pH7.2 (up to 50ml) 
DMEM/10 % FCS 500 ml DMEM 
50 ml FCS, heat-inactivated 
DNA Gel Loading Buffer (10 x) 100 mM Tris/HCl, pH 7.5 
10 mM EDTA 
50 % Glycerol 
1 % Orange G 
Electrical Field Stimulation Solution 135 mM NaCl 
5 mM KCl 
1.5 mM CaCl2 
1.5 mM MgCl2 
20 mM HEPES 
10 mM Glucose 
pH: 7.4 
HBSS  25 mM HEPES pH 7.4 
140 mM NaCl 
5 mM KCl 
1 mM CaCl2 
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1 mM MgCl2 
1 mM Glucose 
0.25% BSA 
Inoue Transformation Buffer for competent cells 10 mM PIPES, pH 6.7 
250 mM KCl 
15 mM CaCl2 
55 mM MnCl2 
K2EGTA Solution for Ca
2+ Titrations 10 mM K2EGTA 
1.5549 mM MgCl2 
MOPS Buffer pH7.2 (up to 50ml) 
LB (Luria-Bertani) medium  20 g/l LB broth base pH 7,0 
in ddH20 
LB Agar LB Medium 
15 g Agar 
in 1 l ddH2O 
Lysis Buffer 250 mM Tris pH 7.5 
5 mM MgCl2 
130 mM NaCl 
10 mM KCl 
1% Triton-X 
5% Glycerin 
MOPS Buffer for fluorescence spectroscopy 10 mM MOPS, pH 7.5 
100 mM KCl 
MOPS Buffer for Ca2+ Titrations 10 mM MOPS, pH 7.2 
100 mM KCl 
Neurobasal/B27  500 ml Neurobasal medium 
10 ml B27 supplement 
Neurobasal/B27 for Electrical Field Stimulation 500 ml Neurobasal medium 
10 ml B27 supplement 
60 mM NaCl 
PBS (10 x) 100 mM Na2HPO4, pH 7.4 
20 mM KH2PO4 
1.37 M NaCl 
27 mM KCl 
Poly-L-Lysine 0.01 % (w/v) Poly-L-Lysine Hydrobromide in H2O 
Protein Resuspension Buffer 20 mM NaPO4, pH 7.8 
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300 mM NaCl 
10% SDS-PAGE Separation Gel 1.25ml 40% Acrylamide Mix 
1.25ml 1.5 M Tris (pH 8.8) 
50 µl 10% SDS (pH 7.2) 
50 µl 10% APS  
2 µl TEMED 
2.4 ml H2O 
5% SDS-PAGE Stacking Gel 250 µl 40% Acrylamide Mix 
250 µl 1.5 M Tris (pH 6.8) 
20 µl 10% SDS (pH 7.2) 
20 µl 10% APS  
2 µl TEMED 
1.44 ml H2O 
10x SDS-PAGE Running Buffer 250 mM  Tris Base 
1.92 M  Glycin 
1%  SDS 
H2O to 1 liter 
TAE (10 x) 8.4 g Tris base 
11.4 ml glacial acetic acid 
20 ml of 0.5 M EDTA, pH 8.0 
H2O to 1 liter 
TAE (1 x) 40 mM Tris-acetate 
1 mM EDTA 
10x TBS 200 mM Tris base 
1.37 M NaCl 
pH 7.6 
H2O to 1 liter 
1x TBS-T 100 ml 10x TBS 
900 ml H2O 
1 ml Tween 20  
10x Western Blot Transfer Buffer 250 mM Tris base 
1.92 M Glycerine 
H2O to 1 litre 
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3.7.4 Chemicals  
Chemical Name Supplier 
Agar Sigma (USA) 
Ampicillin, sodium salt Roth (Germany) 
Anhydrotetracycline hydrochloride Sigma (USA) 
BAPTA, tetrapotassium salt Molecular Probes (USA) 
Ca2+ Calibration Buffer Kit  Molecular Probes (USA) 
Calcium Carbonate Sigma (USA) 
Calcium Chloride, dihydrate Sigma (USA) 
DMSO (Dimethylsulfoxide) Roth (Germany) 
Ethylene glycol tetraacetic acid  (EGTA) Sigma (USA) 
Glucose (D-(+)-Glucose anhydrous, min 99%) Sigma (USA) 
Glycine Merck (Germany) 
HEPES free acid Sigma (USA) 
Imidazole Merck (Germany) 
Ionomycin, calcium salt Sigma (USA) 
Kanamycin, sulphate Roth (Germany) 
Leupeptin hydrochloride Sigma (USA) 
L-Glutamic acid Roth (Germany) 
Lysozyme Sigma (USA) 
Magnesium chloride hexahydrate Merck (Germany) 
MG-132 (Z-Leu-Leu-Leu-al) Sigma (USA) 
MOPS Merck (Germany) 
Nimodipine Merck (Germany) 
Penicillin-Streptomycin Gibco (USA) 
Pepstatin A Sigma (USA) 
Phenylmethylsulfonylfluoride (PMSF) Sigma (USA) 
PIPES Sigma(USA) 
Poly-L-lysine hydrobromide Sigma (USA) 
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Potassium chloride Merck (Germany) 
Potassium Hydroxide Merck (Germany) 
Sodium bicarbonate Sigma (USA) 
Sodium chloride Sigma (USA) 
Sodium phosphate monobasic, anhydrous Sigma (USA) 
Tetrodotoxin (TTX) Merck (Germany) 
Triton-X-100 Sigma (USA) 
Trizma Base Sigma (USA) 
Trypsin Sigma (USA) 
Trypsin-EDTA Gibco (USA) 
Yeast extract Sigma (USA) 
 
3.7.5 Plasmids, bacterial strains and cell-lines 
Plasmid Name Supplier 
pRSETB Invitrogen (USA) 
pCDNA3 Invitrogen (USA) 
pRSFDuet-1 Novagen (Germany) 
pSCA-1 University of Toronto (Dr. Bremner) 
pSCA-Helper University of Toronto (Dr. Bremner) 
Bacterial Strain Supplier 
BL21(DE3) Invitrogen (USA) 
TransforMaxTM EC100TM Electrocompetent E.coli EpiCentre (USA) 
XL-1 Blue Invitrogen (USA) 
Mammalian Cell Line Supplier 
HEK 293T ATCC (USA) 
Hela Invitrogen (USA) 
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4 Results 
 
In order to develop this novel biosensor several progressive stages were undertaken 
(Figure 13). Once the Integrator concept design was determined an in vitro platform was 
required in order to demonstrate that an irreversible change in fluorescence can be elicited in 
response to Ca2+ and serve as a stage for further development. In vitro development and 
optimisation was further performed in order to tailor the fluorescent changes towards Ca2+ 
concentrations resembling neuronal Ca2+ transients (<1 mM) whilst retaining minimal 
spontaneous background activity. Upon completion, cell culture validation was required via 
exposing the Integrator to conditions of repeated neuronal depolarisation. Finally, an induction 
mechanism (or “on switch”) was introduced and validated in order to provide temporal control 
over Integrator expression.  
 
Figure 13: Approach for Integrator biosensor development 
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4.1 Approach 1: Ca2+-dependent protease FRET Integrator 
4.1.1 Exploring the feasibility of a µ-Calpain Integrator  
4.1.1.1 In vitro determination of Reporter specificity 
Two FRET reporters were generated using a Calpain Sensitive Substrate (CSS) and the 
Calpain Insensitive Substrate (CIsS) (Figure 14A) (Vanderklish et al., 2000). Reporters were 
subsequently incubated with 20 µM commercial µ-Calpain (Merck; purified from Porcine 
Erythrocytes) in the presence or absence of 1 mM Ca2+ and the spectra were recorded for 3 
hours (Figure 14B-F). CSS displayed a maximal 64 % FRET cleavage within the first hour with 
1mM Ca2+ compared to 16 % cleavage displayed by CIsS. Both Reporters displayed a 4 % 
reduction without Ca2+ within the first hour (Figure 14B).  
 
Figure 14: In vitro determination of Reporter activity  
A) Schematic illustrating µ-Calpain cleavage sequences for the Calpain Sensitive Substrate (CSS; top) and 
the Calpain Insensitive Substrate (CIsS; bottom). B) FRET Ratio (YFP/CFP) kinetics of 20 µM µ-Calpain 
activity: CSS +1 mM Ca2+ (black), CSS + 0 mM Ca2+ (red), CIsS +1 mM Ca2+ (blue), and CIsS +0 mM Ca2+ 
(green). Error Bars ± SEM. C-F) Fluorescence emission spectra of Reporter at 0 hour (black), 1 and 2 hour 
(grey), and 3 hour (red) with 20 µM Calpain 1. C) CSS +1 mM Ca2+. D) CSS + 0 mM Ca2+. E) CIsS +1 mM 
Ca2+. F) CIsS + 0 mM Ca2+. 
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4.1.1.2 Evaluation of CSS FRET cleavage under physiological Ca2+/Mg2+ conditions 
In order to determine the in vitro physiological Ca2+ range for Reporter activation CSS 
was incubated with 20 µM commercial µ-Calpain in buffered solution containing 0, 0.01, 0.1 
and 1 mM Ca2+ with 1 mM Mg2+ and the FRET ratio was recorded for 3 hours. Ca2+-free and 0.01 
mM Ca2+ displayed a higher rate of FRET reduction (15 % after 3 hours) compared to Mg2+-free 
incubations (8 %) (Figure 15A). In comparison, 0.1 and 1 mM solutions found a similar almost 
maximal FRET reduction within the first hour, comparable with the kinetics observed in Mg2+-
free environments. Despite this a 28 % FRET cleavage in a 1 mM Ca2+, 1 mM Mg2+ solution is 
significantly lower than the 64 % observed in a 1 mM Ca2+ solution (Figure 15B).  
 
Figure 15: In vitro assessment of CSS under physiological Ca2+/ Mg2+ conditions 
A) Kinetics of FRET cleavage (YFP/CFP) of CSS incubated with 20µM µ-Calpain in the presence of 0mM 
(black), 0.01mM (red), 0.1mM (blue) and 1mM (green) Ca2+. B) Fluorescence emission spectra after 3 
hours of FRET cleavage with colour coding identical to A.   
 
 
4.1.1.3 Generation of recombinant µ-Calpain constructs 
In order to implement in vitro rational design modifications to µ-Calpain it was 
necessary to develop a recombinant DNA construct that would serve as the foundation for 
further modification. The large (CAPN1) and small (CAPNS1) subunit were initially combined 
with a mCherry tag (µ-C 1) and with the incubation of µ-C 1 with CSS no significant changes in 
FRET were observed after 1 hour with 1 mM Ca2+ (Figure 16A). Furthermore, increasing the Ca2+ 
concentration to 2 mM or 10 mM did not result in µ-Calpain function (Figure 16B). Alternate 
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strategies included separate expression of CAPN1 and CAPNS1-mCherry that would only be 
expressed in bacteria containing both plasmids due to the Ampicillin resistance of pRSETB and 
the Kanamycin resistance of pRSFDuet (Figure 16D; µ-C 2). Hereby, both subunits were 
expressed in pRSFDuet containing an Internal Ribosomal Entry Site (IRES) for separate 
expression of the two subunits, with and without a mCherry tag (µ-C 3 and µ-C 4 respectively). 
In no case did the expression of these recombinant proteins yield functional protease activity 
(Figure 16C).  
 
Figure 16: In vitro analysis of recombinant CAPN1 and CAPNS1 
A) Fluorescence emission spectra of CSS with µ-C 1 before (black) and after (red) 1 hour incubation with 
10 mM Ca2+. B) Normalised FRET ratio changes of CSS after 1 hour with commercial µ-Calpain (black), or 
µ-Calpain (grey). The x-axis denotes concentration of Ca2+ used for incubation. C) 1 hour 10 mM Ca2+ 
incubations of CSS with µ-C constructs 1-4 (grey) and commercial µ-Calpain (black). D) Schematic 
indicating vectors and structure of recombinant subunits used in this approach.  
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4.2 Approach 2: Artificial Ca2+-dependent protease FRET Integrator 
4.2.1 Approach 2a: Conformation-dependent Protease Integrator 
4.2.1.1 Generating Truncated TEV with mCherry (ΔTEV-Ch) 
In order to generate a screening strategy to determine insertion sites for Troponin C 
(TnC) it was first necessary to engineer a fluorescent tagged TEV. In this case mCherry was used, 
in order to identify bacterial colonies that acquired a Transposon insertion in the correct 
location (Section 3.1.10). Typically, when engineering novel protein function there is often a 
compromise between engineered and wild-type function; for example the split-TEV yield 50% 
proteolytic activity (Wehr et al., 2006). Thus, before the TnC domain was inserted an 
improvement to the TEV protease function was desired. Previous research indicated the 
presence of C-terminal auto-inhibition via 6 amino acids located at the C-terminus (Nunn et al., 
2005). Thus, ΔTEV-Ch was generated via truncation at position 236 and insertion of a mCherry 
tag (Ch) for screening purposes (Figure 17A). Fluorescence spectra of TS-FRET were recorded in 
the presence of either wtTEV (Figure 17B) or ΔTEV-Ch (Figure 17B, C). Over 12 hours both 
proteases demonstrated a maximal 73 % reduction in FRET; however, they displayed 
significantly different kinetic FRET rates. WtTEV displayed a dissociation constant Kd value of 4.3 
hours whereas the ΔTEV-Ch displayed a significantly increased rate of TS-FRET cleavage (Kd: 
0.5h) (Figure 17B). Interestingly, upon maximal cleavage of TS-FRET, the fluorescence emission 
spectra displays only a 5 % dissimilarity compared to CFP alone (Figure 17D) indicating that this 
reduction in FRET corresponds to almost complete TS-FRET cleavage.  
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Figure 17: In vitro kinetics of wild type TEV and ΔTEV-Ch  
A) Schematic representation of the two constructs. TEV consists of 242 amino acids that are reduced to 
236 upon truncation of the autoinhibitory C-terminal domain (ΔTEV). B) Kinetics of TS-FRET cleavage by 
wt TEV (black) and ΔTEV-Ch (red). C) Fluorescence emission spectra of ΔTEV-Ch at 0 hour (black) and 12 
hour (red). D) Fluorescence emission spectra of TS-FRET incubated for 12 hours with ΔTEV-Ch (red) and 
CFP alone (blue). 
 
4.2.1.2 Transposon-based bacterial colony screening 
Using the screening method outlined in Section 3.1.10 a screened population of 
approximately 200 colonies yield a insertion bias with a median quartile (Q2) of 185 amino 
acids (Figure 18A) with the upper (Q3) and lower quartile (Q1) being 210 and 170 respectively. 
From this a sample of 100 was selected and sequenced to ensure insertion in the correct 
reading frame. Once duplicate insertion sites were removed a sample size of 8 were chosen 
that span the Q1 – Q3 range (Figure 18B).  
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Figure 18: Sampling of insertion sites from screened bacterial colonies 
A) Box-plot demonstrating position of transposon insertion site from the N-terminus of TEV. Red line 
indicates C-terminus of the ΔTEV protease. B) Transposon insertion positions (amino acids) of the 8 
member sample used for further investigation.  
 
4.2.1.3 Assessment of Ca2+-dependent protease function 
Assessment of protease function was determined by two steps. The first step involved 
determination of Transposon-inserted ΔTEV-Ch function (samples A-H) compared to insertion-
free ΔTEV-Ch. Purified proteins were incubated for 1 hour with TS-FRET and ΔR/R ratio changes 
were quantified. The majority of Transposon-inserted constructs did not retain and significant 
protease function, however, insertion at position 131 and 197 yield proteases retaining 28 and 
40 % activity respectively (Figure 19A). Regardless, all eight samples underwent the second 
assessment step via the evaluation of protease function upon TnC C-lobe insertion. In 
comparison with ΔTEV-Ch (Figure 19B, C) all constructs displayed an increase in FRET ΔR/R in a 
Ca2+ free environment (Figure 17B, D) indicative of protease interaction-induced FRET (an 
average increase of 20 %). With the addition of Ca2+ a similar FRET increase was observed 
indicating no Ca2+-induced gain of proteolytic function.  
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Figure 19: TnC C-lobe insertion and in vitro functional characterisation  
A) Normalised ΔR/R of TS-FRET after 1 hour incubation with ΔTEV-Ch (black) or Transposon-inserted 
proteases (grey). B) Normalised ΔR/R of TS-FRET after 1 hour incubation alone (green), with ΔTEV-Ch 
(black), or TnC C-lobe inserted proteases in the absence (grey) or presence (red) of 1 mM Ca2+. C) 
Fluorescence emission spectra of TS-FRET before (black) and after (red) 1 hour of ΔTEV-Ch incubation. D) 
Fluorescence emission spectra of TS-FRET incubated with “Sample C” before (black) or after 1 hour 
incubation with (red) and without (blue) CaCl2.  
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4.2.2 Approach 2b: Split TEV Integrator 
4.2.2.1 In vitro development of Ca2+-dependent split TEV protein 
TEV fragments were fused to ΔCaM and ΔM13 in several configurations before each 
protein was purified and measured in vitro with TS-FRET and 1 mM Ca2+. The fluorescence 
emission spectra were recorded for 1 hour (Figure 20A) and compared to control TS-FRET and 
full TEV FRET measurements (Figure 20A inset). The configurations examined included; from 
the N- to C-terminal, TN-CaM/M13-TC, CaM-TN/M13-TC and TC-CaM/M13-TN. After 1 hour a 
maximal 18 % ΔR/R was recorded (Figure 20B), however, this was not due to a ratiometric 
change but rather an increase in ECFP fluorescence only.  Additional purification and in vitro 
characterisation of FRB-TN and FKBP-TC (provided by Moritz Rossner) with the FRB/FKBP 
dimerising agent Rapamycin (1 mM) also failed to display any TS-FRET cleavage (data not 
shown). Thus, it was concluded that this in vitro platform was unsuitable for the evaluation of 
this split TEV architecture. Nevertheless, this Integrator strategy was assessed in dissociated 
hippocampal neurons using electrical field stimulation.  
 
 
Figure 20: In vitro characterisation of split TEV fragments. 
A) Normalised fluorescence emission spectrum of TS-FRET with TN-CaM and M13-TC before (black) and 
after 12 hours with 1 mM Ca2+ (red). Fluorescence emission spectrum of TS-FRET incubated with full TEV 
is also shown for comparison (inset; identical colour coding). B) Normalised ΔR/R of TS-FRET with full 
TEV control (black) and split TEV configurations (grey).  
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4.2.3 Calibration and application of Electrical Field Stimulation 
In order to determine the functionality and operational parameters of Electrical Field 
Stimulation a series of stimulation experiments were conducted on dissociated hippocampal 
neurons using the Ca2+ dye Fluo-4-AM. The parameters (Burst Duration (BD), Stimulation 
Frequency (SF), pulse width (PW) and field strength (FS)) were each investigated in turn. In all 
cases a maximal ΔF/F of 60 % was reached (Figure 21). By this calibration it was determined 
that a 1 s pulse duration of 80 Hz frequency with a 1000 µs pulse width at 30 V would be 
appropriate stimulation parameters.   
 
Figure 21: Configuration of Electrical Field Stimulation using Fluo-4-AM  
A) Normalised ΔF/F responses of Fluo-4 to a series of burst durations (BD) ranging from 0.5 to 3 sec. B) 
Normalised ΔF/F responses to a pulse frequency (PF) range of 20-160 Hz. C) Normalised ΔF/F responses 
to a pulse width PW) range of 200-1200 µs. D) Normalised ΔF/F responses to applied field strengths (FS) 
of 10-30 V. Insets: 30 sec ΔF/F traces for each parameter value (monochrome gradient for lowest (light 
grey) to highest value (black) measured).  Error bars ±SD. 
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Using the LIVE/DEAD cytotoxicity assay a burst (80 Hz PF, 1000 µs PW, 1 sec BD, at 30 V), 
with an intertrain interval (ITI) of 4 min, was shown to confer no significant effect on cell 
survival after 4 hours (Figure 22A, B) based on the ratio of live cells compared to all live and 
dead cells (Figure 22C). Based on structural studies determining the orientation of CaM-CBP 
interaction (Ishida and Vogel, 2006) the TN-CaM/M13-TC pair was chosen for dissociated 
hippocampal neuron studies. Ultimately a 2 hour stimulation timeframe was unable to induce 
significant cleavage of the TS-FRET pair compared to the stimulus-free condition (Figure 22D).  
 
Figure 22: Cell stimulation frequency determination and application to split-TEV 
A) Normalised fluorescence responses of Fluo-4 to an 80 Hz PF, 1000 µs PW, 1 sec BD, 30 V FS burst 
every 4 min. B) Quantification of cell survival using a 4 min pulse for up to 4 hours. C) Artificially 
coloured fluorescent microscopy images of the markers for cell survival (Calcein) and cell death (EthD-1), 
scale bar 50 µm. D) ΔR/R values for dissociated neurons stimulated for 2 hours with a burst every 4 min 
(black) or unstimulated (red). Error bars ±SD. 
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4.3 Approach 3: Bimolecular Fluorescence Complementation Integrator 
4.3.1 In vitro optimisation of Integrator 
4.3.1.1 Determination of appropriate location for splitting Citrine 
Previous research identified two fragmentation sites where Aequorea Victoria-derived 
FPs can be split to yield the highest signal-to-background ratio (inducible complementation 
versus spontaneous association of fragments); the 155 and 173 amino acid positions (Hu and 
Kerppola, 2003). In order to determine the most suitable split site the two Citrine (denoted as 
“Y” for “YFP”) combinations were integrated into a YN-ΔCaM and ΔM13-YC construction. Over 4 
hours in vitro analysis of 154/155 protein recombination found a 470 % increase in Ca2+-
dependent complementation (signal) over spontaneous association (background) whereas 
using the 172/173 split a 65 % increase was observed (Figure 23A, B). Furthermore, the 
172/173 split displayed a total complementation of 29 % compared to that of the 154/155 split 
leading to the selection of the 154/155 citrine fragments for further development.  
 
 
Figure 23: In vitro analysis of the 155 and 173 split Citrine. 
A) Co-incubation of YN1-154-ΔCaM with ΔM13-YC155-238 in the presence (black) or absence (red) of 1 
mM CaCl2. B) Co-incubation of YN1-172-ΔCaM with ΔM13-YC173-238 in the presence (black) or absence 
(red) of 1 mM CaCl2. 
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4.3.1.2 Determination of spontaneously interacting proteins 
In order to yield maximal signal (Ca2+-induced complementation) several steps were 
undertaken. The first step was to identify the source for the Ca2+-free spontaneous background 
fluorescence observed in order to reduce the likelihood of high background Citrine fluorescence 
in cells. To determine whether the ΔCaM/ΔM13 or YN154/YC155 interactions were responsible 
for the Ca2+-free complementation observed in Figure 23A the Citrine fragments were purified 
without ΔCaM or ΔM13. A 4 hour co-incubation of the YN or YC components (with the 
complementing component retaining the CaM or M13) yielded no significant change in 
fluorescence (Figure 24A). Thus, the ΔCaM/ΔM13 interaction was found to be responsible for 
the observed background complementation. Due to the ΔCaM and ΔM13 originating from a 
redesigned GECI architecture the determination of whether improvement in the signal or a 
reduction in background could be achieved using wtCaM or wtM13 was carried out. In 
comparison to the 470 % signal/background ratio observed with YN-ΔCaM and ΔM13-YC only a 
250 % ratio was detected with wtCaM and wtM13 with a significant reduction in the overall 
signal (Figure 24B). In contrast the ΔCaM/wtM13 and wtCaM/ΔM13 combinations displayed a 
higher level of background complementation compared to the 1 mM Ca2+ environment. 
Hereby, the ΔCaM/ΔM13 combination is the most suitable combination for further 
development.  
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Figure 24: In vitro spectrophotometric analysis of spontaneous association  
A) Co-incubation of YN1-154-ΔCaM with ΔM13-YC155-238 in the presence (black) or absence (red) of 1 
mM CaCl2. Co-incubation of YN/ΔM13-YC155 (green) or YN154-ΔCaM/YC (blue) in 1 mM CaCl2. B) Citrine 
intensity after 4 hours of incubation of combinations of wtCaM, ΔCaM, wtM13, and ΔM13 with (white) 
and without (grey) 1 mM CaCl2. 
 
4.3.1.3 In vitro optimisation of the ΔCaM/ΔM13 orientation 
During the design phase the orientation of ΔCaM and ΔM13 templates were defined 
based on the binding profile identified by the structural determination of GCaMP2 (Akerboom 
et al., 2009). Consequently, implementation of alternative orientations may yield improved 
signal/background ratios. To achieve this several components were generated; 4 for ΔCaM and 
4 for ΔM13, each with N- or C- terminal YN or YC fragments. After 4 hours incubation two 
orientations yield the highest signal/background ratio, the original YN-ΔCaM/ΔM13-YC 
construction and a ΔCaM-YN/ΔM13-YC construction (Figure 25). In vitro kinetics displayed a 
reduced signal increase for ΔCaM-YN/ΔM13-YC compared to the original orientation with a 
further increased rate of background signal. Therefore, the original orientation was maintained 
for further development.  
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Figure 25: In vitro orientation specificity of complementation  
A) 4 hour end-point Citrine intensity measurements for the 8 orientation combinations with (F2) and 
without (F1) 1 mM CaCl2. B) Kinetics of Citrine refolding of YN-ΔCaM/ΔM13-YC with (black) and without 
(red) 1mM CaCl2. ΔCaM-YN/ΔM13-YC with (blue) and without (green) 1 mM CaCl2.  
 
4.3.1.4 In vitro assessment of alternative FPs for fluorescence complementation 
In order to further optimise the complementation Integrator, alternative FPs were 
considered which could potentially improve the signal/background ratio or generate a more red 
shifted Integrator. In order to achieve this several proteins were split either at the 155 amino 
acid position or in some cases the 159 position (corresponding to the end of the β-sheet), using 
the optimal CaM/M13 orientation described previously. In addition, the YN172/CC155 
complementation pair was also investigated due to the previously reported in vitro success of 
this approach (Hu and Kerppola, 2003). After 4 hours the excitation and emission spectra were 
recorded (Figure 26A).  In the majority of cases no complementation was observed, however, 
the YN172/CC155 combination yield a 238 % improvement over the YN/YC with a significantly 
broader excitation spectrum (Figure 26B). In addition the YN/CC possessed excitation maxima 
of 490 nm, a CFP/Citrine intermediate. Unfortunately, due to the 10-fold increase in 
background fluorescence this was not seen as an improved substitute for the YN/YC fragments 
(Figure 26C). 
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Figure 26: In vitro complementation of alternative FP candidates  
A) 4 hour end point fluorescence of split FPs; Y-YFP, C-CFP, mKO-mKusabira Orange, mKO2, mTFP-Teal 
FP, mOr-mOrange, mCh-mCherry, mKate, TagRFP. B) Fluorescence excitation spectra of YN154-
ΔCaM/ΔM13-YC155 (black) and YN172-ΔCaM/ΔM13-CC155 (red). C) Fluorescence emission spectra of 
YN154/YC155 with 1 mM CaCl2 (black), 0 mM CaCl2 (red) and YN172/CC155 with 1 mM CaCl2 (blue), 0 
mM CaCl2 (green).  
 
4.3.1.5 Cell-based validation of YN154-ΔCaM and ΔM13-YC155  
With the in vitro verification of the most optimal Integrator architecture the assessment 
of biosensor characteristics in cells was performed. Transient transfection of HEK293T cells with 
YN-ΔCaM and ΔM13-YC revealed that 33 % of cells expressing CFP exhibited Citrine background 
fluorescence (Figure 27A, C). Furthermore, of these background-positive cells, the overall YFP 
fluorescence was 29 % as bright as CFP (Figure 27A, B). In order to confirm biosensor function, 
dissociated hippocampal neurons were transiently transfected with the two components 
before application of the stimulation protocol for 4 hours (80 Hz PF, 1000 µs PW, 1 sec BD, 30 V 
FS) whereby no significant increase in signal was observed (Figure 27D). 
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Figure 27: Cell culture characterisation of YN-ΔCaM and ΔM13-YC  
A) Fluorescence microscopy images of HEK293T transiently transfected with YN-ΔCaM and ΔM13-YC 
(arrow heads denote cells expressing CFP but no YFP). B) Citrine/CFP ratio of HEK293T cells. C) 
Percentage of HEK293T cells exhibiting spontaneous association (background) yielding Citrine 
fluorescence. D) Citrine ΔF/F of hippocampal neurons stimulated with an 80 Hz PF, 1000 µs PW, 1 sec 
BD, 30 V FS pulse every 4 min for 4 hours. B+C error bars ±SD, D, error bars ±SEM. 
 
 
4.3.1.6 In vitro Peptide screen 
To reduce the background of YN154-ΔCaM/ΔM13-YC155 observed in HEK293T cells 
(Figure 27B) a peptide screen was undertaken in a 96-well plate using all currently known Ca2+-
dependent CaM binding peptides (Yamniuk and Vogel, 2004). A final concentration of 1.5 µM 
for each component was used and the proteins were incubated for 4 hours before measuring 
the Citrine emission (Figure 28A). This resulted in the identification of a novel peptide, the 
ΔSpectrin (lacking a Histidine at position 14 compared to the wt Spectrin sequence; 
KTASPWKSARLMVHTVATFNSIKE), that exhibited a higher signal/background ratio compared to 
the ΔM13 peptide. Kinetic studies found a 130 % increase in signal of ΔSpectrin (ΔSp) compared 
to ΔM13 with an additional 3-fold improvement in the signal/background ratio (Figure 28B). 
When transiently transfected in HEK293T cells (along with a CFP marker) ΔSp also displayed 
significantly lower background fluorescence that was 85 % lower compared to ΔM13 (Figure 
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28C, E). Additionally there was a significant 16 % reduction in the number of cells exhibiting 
background fluorescence when using ΔSp compared to ΔM13 (Figure 28D, E).  
 
 
Figure 28: In vitro peptide screen and HEK293T ΔM13/ΔSpectrin comparison  
A) 4 hour 96-well plate end point fluorescence of Ca2+-dependent CBPs. B) Cuvette fluorescence 
emission kinetics of YN-CaM with ΔM13-YC (black) and ΔSpectrin (red) with 1 mM Ca2+ (filled circles) or 0 
mM Ca2+ (open squares). C) Recombined Citrine/CFP ratio of ΔM13-YC (white) or ΔSpectrin-YC (grey) in 
HEK293T cells. D) Percentage of HEK293T cells containing spontaneous background complementation; 
ΔM13-YC: White, ΔSpectrin-YC: Grey. E) Fluorescence microscopy images of ΔM13 and ΔSpectrin, scale 
bar 50 µm. ***p<0.001, **p<0.02. B error bars ±SEM, D, error bars ±SD. 
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4.3.1.7 In vitro assessment of alternative Citrine fragmentation sites  
With a significantly improved signal/background ratio using ΔSp the remaining 
background fluorescence was hypothesised to be due to the optimal complementation of 
Citrine, and thus, by modification of the split location a further improvement in the 
signal/background ratio could be achieved. In order to investigate this several Citrine fragments 
were generated; YN154/ YC155 (original fragments), YN152, YN153, and YC154, that were fused 
to ΔCaM or ΔSp. Combinations were generated to result in a shift in split location into the β-
sheet (YN153/ YC154) or to add or subtract an amino acid (YN154/ YC154 or YN152/ YC154 
respectively) (Figure 29A). By shifting the split location to YN153/ YC154 a 27 % increase signal 
and a 22 % reduction in background were observed in vitro (Figure 29B). By comparison, the 
addition or subtraction of an amino acid yielded a reduction in the signal (23 % and 34 % 
respectively) with no decrease in background fluorescence. Thus the components YN153-ΔCaM 
and ΔSp-YC154 were selected for continuation. 
 
Figure 29: In vitro complementation of alternative fragmentation sites  
A) Structural representation of alternative fragmentation sites. Yellow: N-fragment, orange: C-fragment, 
blue: fragment position. B) 4 hour end point in vitro fluorescence of alternative fragmentation sites co-
incubated with 1 mM CaCl2 (grey) or without (white). Error bars ± SEM. 
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4.3.1.8 Temperature dependency of fluorescence complementation 
All in vitro experiments previously mentioned were performed at room temperature 
(RT), however, previous research has shown a strong temperature dependency of 
complementation (Robida and Kerppola, 2009). To determine the effect temperature played on 
Integrator function two questions were addressed; i) what effect does temperature have on 
complementation alone and ii) does temperature affect Integrator Ca2+ sensitivity? Firstly, to 
determine the temperature effect on complementation alone protein samples of YN-ΔCaM and 
ΔSp-YC were incubated for 4 hours at a temperature gradient ranging from RT to 37 oC in a 1 
mM Ca2+ saturated environment. Interestingly no reduction in signal was observed at higher 
temperatures; however, a significant decrease in the background fluorescence was detected 
with increasing temperature (Figure 30A). Secondly, in order to determine temperature effects 
on both ΔCaM/Ca2+ binding and ΔCaM/ΔSp interaction, a Ca2+ titration series was generated to 
represent more physiological Ca2+ and Mg2+ ranges. YN-ΔCaM and ΔSp-YC were incubated for 4 
hour with a Ca2+ range of 0 - 38.7 µM (for RT) or 0 – 36.0µM (37 oC). For evaluation of Ca2+ 
titrations two criteria were considered: the EC50 (the concentration of Ca
2+ that elicits 50% total 
complementation), and the total Ca2+-mediated complementation. In comparison to RT a 380 % 
reduction in total signal was observed at 37 oC and an additional decrease in Ca2+ sensitivity was 
observed by the increase in EC50 from 811 nM at RT to 2000 nM at 37 
oC (Figure 30B).  
 
Figure 30: In vitro temperature dependency of fluorescence complementation  
A) Citrine fluorescence of components YN-ΔCaM and ΔSp-YC measured after 4 hours with (grey) and 
without (black) 1 mM CaCl2. B) Ca
2+ titration at RT (red) or 37 oC (black). Error bars ± SEM. 
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4.3.1.9 Cell-based validation of YN153-ΔCaM and ΔSp154-YC  
As the cell characterised ΔM13 peptide was replaced with the mutant ΔSp peptide it 
was necessary to first ascertain whether the ΔSp peptide formed complementation complexes 
with ΔCaM in a cellular environment. Exposure of transiently transfected HEK293T cells to high 
external Ca2+ concentrations via application of the ionophore “Ionomycin” resulted in a 214 % 
increase in the [YN+YC]/CFP ratio compared to control groups thus indicating a Ca2+-dependent 
interaction ΔCaM/ΔSp (Figure 31A). Furthermore, to determine Integrator responses to 
endogenous Ca2+ transients Electrical Field Stimulation was applied to transiently transfected 
neurons with no significant change in the ΔF/F of Citrine detected (Figure 31B, C). 
 
Figure 31: Cell culture characterisation of YN-ΔCaM and ΔSp-YC  
A) HEK293T cells transfected with 3 µg (white) or 1.5 µg (grey) total DNA concentration. Cells were 
treated for 4 hours with 1 µM Ionomycin alone or with an additional 5 mM CaCl2. B) Fluorescence 
microscope images of stimulated neurons, scale bar 50 µm. C) Live cell imaging ΔF/F values for 
transfected hippocampal neurons stimulated with 80 Hz, 1000 µs, 1 sec, 30 V burst every 4 minutes. 
***p<0.001. A error bars ± SD. C, error bars ± SEM. 
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4.3.2 Integrator refinement for response to endogenous Ca2+ transients 
With the success of developing a complementation-based Integrator responsive to 
exogenous Ca2+ application the next developmental step was to determine the Integrator’s 
response to endogenous stimuli - a task that has not previously been achieved by the 
complementation field. Until now Integrator development has included not only optimisation 
of the fundamental architecture of the design (orientation, split location, and FP) but also the 
implementation of a new CaM binding peptide (ΔSp) specifically for the application of a CaM-
peptide Integrator. The ensuing optimisation was directed towards improving the Ca2+ 
specificity of the CaM/ΔSp as well as improving the stability of the second component, ΔSp-
YC154, and investigating whether by the addition of linkers the biosensor function could be 
improved. 
 
4.3.2.1 Linker-based strategy for improving complementation 
Recent research has highlighted the often understated impact that flexible linkers have 
on biosensor analyte affinity (Horikawa et al., 2010). The design architecture exploited by the 
complementation-based Integrator did not possess any linkers as it was logical that the addition 
of such linkers would increase the likelihood of background complementation. In order to 
investigate whether the signal could be improved by increasing the flexibility of ΔCaM or ΔSp 
three poly-glycine linkers were incorporated into both components with varying length (GGS, 
GGGS, and GGGGS). When the linkers were inserted between the YN153 and ΔCaM a respective 
60, 30, 46 % reduction in the total complementation was observed (Figure 32A) with no 
improvement to Ca2+ affinity (EC50: 2800, 3800, 2800 nM respectively). Similarly, when the GGS 
and GGGS were inserted in-between the ΔSp-YC154 a respective 19 and 52 % reduction in 
complementation was observed with no improvement to Ca2+affinity (EC50: 2800 and 3800 nM 
respectively) (Figure 32B). In contrast, addition of a GGGGS linker resulted in a 31 % increase in 
complementation independent of EC50 improvement.  
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Figure 32: Ca2+ titrations of linker-modified components  
A) Linkers integrated in-between YN153 and ΔCaM; Black: No linker, Red: GGS, Blue: GGGS, Green: 
GGGGS. Each sample was co-incubated with ΔSp- YC154. B) Linkers integrated in-between ΔSp and 
YC154; Black: No linker, Red: GGS, Blue: GGGS, Green: GGGGS. Each sample was co-incubated with 
YN153-ΔCaM. Error bars ± SEM. 
 
4.3.2.2 Improving the Ca2+-coordination of the ΔCaM component 
In parallel, an alternative approach to increase the Ca2+ affinity of the Integrator was 
undertaken by the improvement of the coordination of Ca2+ in EF-hands II and III of CaM. Two 
positions were selected, N60 and N97 that were mutated to aspartate residues (N60D, N97D), 
one located in the low affinity N-lobe and the other in the high affinity C-lobe (Figure 33A). CaM 
mutants were generated individually or in tandem yielding varied outcomes (Figure 33B). Using 
the linker-free ΔSp-YC154 the N60D and N97D single mutations did not yield any increase in 
Ca2+ affinity (EC50: 2900 nM, and 2800 nM respectively), however an 86 % increase in total 
complementation was observed with the N60D mutation. Additionally, the incorporation of 
both mutations resulted in a 115 % improvement in total complementation with an improved 
EC50 of 1460 nM. However, in combination with ΔSp-GGGGS this improvement was not 
maintained as the Ca2+-mediated complementation exhibited a 94 % reduction compared with 
the linker-free ΔSp-YC154 and an additional reduction in Ca2+ affinity was observed (1730nM) 
(Figure 33C). Thus, the linker was discarded and the CaMN60DN97D mutations were retained for 
further Integrator development.  
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Figure 33: Ca2+ titrations of CaM mutations  
A) Schematic illustrating the mutation points within the N- and C-lobe (Red: mutation sites). B) Ca2+ 
titrations of the original ΔCaM (black), N60D (blue), N97D (red) and N60DN97D (green) with the ΔSp-
YC154. C) Ca2+ titrations of the original ΔCaM/ΔSp combination (black), CaMN60DN97D/ ΔSp (grey), and the 
CaMN60DN97D/ ΔSp-GGGGS (red). Error bars ± SEM. 
 
4.3.2.3 Improving the stability of the ΔSp component  
One central dogma of the ubiquitin system, the “N-end rule”, stipulates that the N-
terminal residue possesses the capacity to induce primary, secondary, or tertiary destabilisation 
(Varshavsky, 2008). The component ΔSp-YC possessed an N-terminal degradation residue (N-
Degron) and without internal structure (due to the fusion of a short peptide to several β-sheets) 
it was postulated that stabilisation of this component via N- and C- terminal modification would 
enhance protein stability in a cellular environment. The first point of investigation was the 
addition of a C-terminal FP that would not only aid the stabilisation of the overall component 
but also provide a constitutive FP that would negate the requirement of an additional FP to be 
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transfected.  Two FPs were considered, ECFP and ΔECFP (S30R Y39N A206K) with additional 
mutations for enhancing folding rate (Figure 34A). In vitro analysis of the ΔSp-YC-ECFP 
component exhibited 567 % reduced fluorescence in comparison to ΔSp-YC-ΔECFP (Figure 34B). 
Ca2+ titrations with YN-CaMN60DN97D found that ΔSp-YC-ΔECFP enhanced the total 
complementation by 115 % with a negligible decrease in Ca2+ sensitivity (EC50: 1510 nM). In 
contrast, by the addition of ECFP a 67 % decrease in signal and a significantly lower Ca2+ 
sensitivity of 2900 nM were observed (Figure 34C). Interestingly, as both ECFP variants 
displayed similar FRET ratio changes of 100 % neither variant conferred significant signal-to-
noise improvements to rival that observed by complementation (Figure 34D).  
 
Figure 34: In vitro C-terminal incorporation of CFP variants  
A) Schematic illustrating the architecture of the ΔSp component with the incorporation of ECFP or 
ΔECFP (S30R, Y39N, A206K). B) Fluorescence excitation and emission spectra of the two variants. Red: 
ECFP, Blue: ΔECFP. C) Complementation Ca2+ titrations of the original ΔSp (black), ΔSp-YC-ECFP (red), 
and ΔSp-YC- ΔECFP (blue) with YN-ΔCaMN60DN97D. C) FRET ratio (527/475nm) Ca2+ titrations of the YN-
ΔCaMN60DN97D with either ΔSp-YC-ECFP (red), or ΔSp-YC ΔECFP (blue). Error bars ± SEM. 
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To prevent the primary and secondary destabilisation induced by the ΔSp N-Degron 
(Lys) several N-terminal sequence “caps” were generated with varying length; V, VA, VAA, and 
VAAA. In vitro analysis found that the majority of N-terminal modified components; V, VA, and 
VAAA induced a reduction in total complementation (10, 5 and 18 % respectively) and Ca2+ 
affinity (1700, 1690, and 1615 nM respectively) (Figure 35A). In contrast the VAA N-terminal 
cap induced a 17 % increase in complementation and a significant increase in Ca2+ affinity, 650 
nM (Figure 35B).  
For cellular stability analysis each of the N-terminal modified constructs were expressed 
in HEK293T cells with and without the addition of the proteasome inhibitor MG-132. In 
comparison to the transient transfection of ΔECFP alone, the original ΔSp sequence, beginning 
with the amino acids KT (Lys-Thr), exhibited 10.4 ± 0.8 % CFP fluorescence that increased to 
36.5 ± 1.8 % CFP fluorescence in the presence of the proteasome inhibitor MG-132 (Figure 
35C). In comparison to the original protein, all N-terminal modified sequences exhibited higher 
levels of CFP fluorescence of approximately 30 % of ΔECFP and increased to ~65 %. With the 
assumption that degradation-free CFP fluorescence (+10 µM MG-132) corresponds to maximal 
achievable fluorescence for this component it was found that, under cellular conditions, the 
original ΔSp peptide exhibited 28 ± 0.7 % fluorescence. However, by the stabilisation of the N-
terminus a statistically significant higher fluorescence of ~50 % was recorded for all modified 
components (that did not display significant difference between themselves) indicating a 150 % 
reduction in proteasome-directed degradation (Figure 35D).  
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Figure 35: In vitro and cell culture characterisation of N-terminal modified components  
A) Ca2+ titrations of YN-ΔCaMN60DN97D with; black: ΔSp (YC- ΔECFP), red: VΔSp, blue: VAΔSp, orange: 
VAAAΔSp. B) Ca2+ titrations of YN-ΔCaMN60DN97D with; black: ΔSp, green: VAAΔSp. C) Normalised CFP 
fluorescence of HEK293T cells transfected with components possessing the N-terminal sequence KT 
(original), V, VA, VAA or VAAA (white/light grey). Cells co-incubated with 10 µM MG-132 are shown in 
grey/dark grey. D) Component CFP fluorescence under non-inhibited conditions as a percentage of 
maximal CFP fluorescence achieved using MG-132. **p<0.02. A+B error bars ± SEM, C+D error bars ± SD. 
 
 
Finally, to ascertain whether the C-terminal incorporation of ΔECFP provided additional 
stability in cells, ΔECFP was replaced by ECFP. Hereby, ECFP  a 67 % reduction (18.5 ± 1.6 %) of 
fluorescence in inhibitor-free conditions and a 42 % reduction (41.5 ± 1.3 %) in the presence of 
MG-132 when compared to ΔECFP (Figure 36A). Thus, the 51 ± 2.9 % of CFP fluorescence 
observed with VAAΔSp-YC-ΔECFP in the presence of active proteasome was reduced to 42.7 ± 
1.9 % with the substitution of ECFP (Figure 36B). 
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Figure 36: Cell culture characterisation of C-terminal modified components  
A) Normalised CFP fluorescence of HEK293T cells transfected with components possessing the N-
terminal sequence VAAA and either a C-terminal ECFP or ΔECFP (white). Cells co-incubated with 10 µM 
MG-132 are shown in grey. B) Component CFP fluorescence under non-inhibited conditions as a 
percentage of maximal CFP fluorescence achieved using MG-132. *p<0.05. Error bars ± SD. 
 
 
4.3.2.4 Enhancing CaM affinity of VAA-ΔSp 
The final point of investigation into Integrator modification was to improve the peptide 
affinity for CaM by the substitution of ΔSp residues for Alanine residues (Montigiani et al., 
1996). Several ΔSp peptides were generated with mutations spanning the positions K7, S8A, 
L11A, F18A and S20A. In vitro Ca2+ titrations revealed an 82 % and 52 % reduction in 
complementation for the K7A and S20A peptides respectively. S8A yield no significant 
difference in complementation and the L11A and F18A exhibited a respective 62 and 85 % 
increase in complementation (Figure 37A). The Ca2+ affinities of the peptides found that, of the 
two peptides, the F18A mutation yield the most significant improvement with an EC50 of 420 
nM (Figure 37B).   
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Figure 37: In vitro characterisation of VAAΔSp peptide mutants  
A) 4 hour Ca2+ titrations of YN-ΔCaMN60DN97D with; black: “wt” (VAAΔSp-YC- ΔECFP), light grey: K7A, red: 
S8A, blue: L11A, green: F18A, grey: S20A. B) EC50 values for all modified peptides.  
 
4.3.2.5 Characterisation of ΔCaMN60DN97D and VAA-ΔSpF18A 
To characterise the fundamental properties of the two Integrator components several 
points were investigated in vitro and in cell culture. The irreversibility of complementation of 
the YN153-ΔCaMN60DN97D and VAAΔSpF18A-YC154-ΔECFP components was validated using 
complementation kinetic studies. In vitro studies using 1 mM CaCl2 and application of the Ca
2+ 
chelating agent BAPTA (20 mM) after 0.5 or 1 hour resulted in an almost instantaneous 
cessation in complementation (Figure 38A). Furthermore, to complete the in vitro 
characterisation of this peptide a comparison of time-resolved complementation kinetics were 
undertaken at physiologically relevant Ca2+ concentrations of 0, 120, 373, 711 and 1100 nM 
CaCl2 (1 mM MgCl2) (Figure 38B).   
In order to determine the interaction properties of the modified CaM and the ΔSp 
peptide in a cellular environment it was necessary to determine to what extent background was 
observed in cells in terms of both the degree of background (measured by fluorescence 
intensity) and the percentage of cell population that displayed background fluorescence. With 
YN-ΔCaMN60DN97D and VAA-ΔSpF18A-YC- ΔECFP background fluorescence was observed in 28 % of 
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HEK293T cells, similar to the ΔCaM/ΔM13 combination, however significantly higher than 
ΔCaM/ΔSp (Figure 38C). Despite the increase in the number of background fluorescence 
positive cells, a slight increase in the background fluorescence (Citrine/CFP Ratio) of YN-
CaMN60DN97D and VAA-ΔSpF18A-YC was noted in comparison to ΔCaM/ΔSp (with CFP transfected 
separately). Nevertheless, the background fluorescence observed was still significantly lower 
than that observed using the ΔCaM/ΔM13 original components (Figure 38D).  
 
Figure 38: Characterisation of Integrator behaviour in vitro and in HEK293T cells  
A) Complementation kinetics of YN153-ΔCaMN60DN97D and VAAΔSpF18A-YC154- ΔECFP in a 1mM CaCl2 
solution (black). 20 mM BAPTA was added after 0.5 hour (red) or 1 hour (blue). B) Complementation 
kinetics of YN153-ΔCaMN60DN97D and VAAΔSpF18A-YC154- ΔECFP in CaCl2 solutions of 0 (black), 120 nM 
(red), 373 nM (blue), 711nM (green), or 1100nM (dark blue) with 1 mM MgCl2. C) Percentage of 
HEK293T cells exhibiting background fluorescence. Black: YC-ΔCaMN60DN97D/ VAA-ΔSpF18A-YC- ΔECFP, 
white: YN-ΔCaM/ΔM13-YC, grey: YN-ΔCaM/ΔSp-YC. D) Ratio of complementation observed in 
background positive cells compared to ECFP.  Black: YN-ΔCaMN60DN97D/ VAA-ΔSpF18A-YC, white: YN-
ΔCaM/ΔM13-YC, grey: YN-ΔCaM/ΔSp-YC. *p<0.05, **p<0.02, ***p<0.001. A, B error bars ±SEM. C, D 
error bars ±SD. 
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4.3.2.6 Cell-based validation of ΔCaMN60DN97D and VAA-ΔSpF18A interaction specificity 
For the evaluation of the interaction between CaM and peptides Bimolecular 
Fluorescence Complementation cannot be used due to its dependency on two factors, the 
interaction between the CaM and peptide and whether this interaction is sufficient to yield the 
irreversible complementation. Therefore the binding efficiency of CaMN60DN97D and VAA-ΔSpF18A 
was determined by replacing the Citrine fragments YN and YC with ECFP and Citrine 
(respectively), thus, changing the irreversible output of the Ca2+-dependent interaction into a 
reversible FRET-based mechanism (Figure 39A).  Under stimulation-free conditions the 
Citrine/CFP ratio of ΔCaMN60DN97D/ VAA-ΔSpF18A did not significantly differ from ΔCaM/ΔM13. 
However, by replacing ΔCaMN60DN97D with wtCaM a significant decrease was observed (Figure 
39B). Using electrical stimulation ECFP-ΔCaMN60DN97D and VAA-ΔSpF18A-Citrine exhibited a 285 % 
higher ΔR/R compared to ECFP-ΔCaM and ΔM13-Citrine (Figure 39C). Additionally, VAA-ΔSpF18A 
possessed a 10-fold higher specificity for ΔCaMN60DN97D compared to wtCaM (Figure 39D). 
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Figure 39: ΔCaMN60DN97D and VAA-ΔSpF18A interaction specificity in cell culture  
A) Schematic illustrating the architecture of the CaM/peptide pairs used; ΔCaM/ ΔM13, ΔCaMN60DN97D/ 
ΔVAA-SpF18A, and wtCaM/ ΔVAA-SpF18A. B) Citrine/CFP ratios of dissociated hippocampal neurons 
transiently transfected with ECFP-ΔCaM/ΔM13-Citrine (black), ECFP-ΔCaMN60DN97D/ VAA-ΔSpF18A-Citrine 
(red), ECFP-wtCaM/ΔVAA-ΔSpF18A-Citrine (blue). C) Normalised ΔR/R values for ECFP-ΔCaM/ΔM13-
Citrine (black), ECFP-ΔCaMN60DN97D/ VAA-ΔSpF18A-Citrine (red) transfected neurons stimulated with an 
stimulation pulse (80 Hz PF, 1000 µs PW, 1 sec BD, 30 V FS) applied once every 20 sec for 2 minutes 
(insert). D) Normalised ΔR/R values for ECFP-ΔCaMN60DN97D/ VAA-ΔSpF18A-Citrine (red), ECFP-wtCaM/Δ 
VAA-ΔSpF18A-Citrine (blue) transfected neurons stimulated with a stimulation pulse (80Hz PF, 1000µs 
PW, 1sec BD, 30V FS) applied once every 20 sec for 2 min (insert). **p<0.02.  Error bars ±SEM. 
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4.3.2.7 Determination of cellular response of YN-ΔCaMN60DN97D-IRES-VAA-ΔSpF18A -YC- ΔECFP  
To unify the two components of this biosensor an Internal Ribosomal Entry Site (IRES) 
was introduced with the two components flanking either terminus. Under this construction the 
first component, the YN-ΔCaMN60DN97D was under the vector CMV promoter and the VAA-
ΔSpF18A -YC-ΔECFP under the IRES promoter (Figure 40A). Transient co-transfection of 
dissociated hippocampal neurons with the red GECI “R-GECO1” (Zhao et al., 2011) and the 
Integrator exhibited a stimulation-dependent 223 % increase in Citrine complementation 
(Figure 40B, D). However, no such increase was observed in unstimulated neurons (Figure 40C, 
E). Furthermore, using a 12-well stimulation chamber it was possible to resolve 
complementation/constitutive FP ratios between unstimulated cells (T=0) and cells stimulated 
for 1 to 4 hours (Figure 40F), whereas substitution of YN-ΔCaMN60DN97D for wtCaM did not yield 
a significant increase in complementation.  
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Figure 40: Cell culture evaluation of Integrator coexpressed with R-GECO1  
A) Schematic of unified components flanking an IRES site. B) Normalised R-GECO1 fluorescence of 
transiently transfected neuron stimulated with electrical field stimulation (using 80 Hz PF, 1000 µs PW, 1 
s BD, 30 V FS, 240 s ITI). C) Normalised R-GECO1 fluorescence of transiently transfected unstimulated 
neuron.  D) ΔECFP and Citrine ΔF/F values of co-transfected Integrator from the same stimulated neuron 
displayed in B. E) ΔECFP and Citrine ΔF/F values of co-transfected Integrator from the same 
unstimulated neuron displayed in C.  F) Reconstituted Citrine/CFP ratio of dissociated hippocampal 
neurons stimulated using a 12-well plate stimulation array. Red: YN-ΔCaMN60DN97D-IRES-VAA-ΔSpF18A-YC-
ΔECFP, black, YN-wtCaM-IRES-VAA-ΔSpF18A-YC-ΔECFP. *p<0.05, ***p<0.001. Scale bar: 50 µm. Error bars 
± SD. 
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4.3.3 Semliki Forest Virus delivery of Integrator 
Due to the irreversible nature of this Integrator the final criteria remaining was the 
generation of a virus containing the Integrator in order to acquire temporal control over 
Integrator expression. The Semliki Forest Virus (SFV) was chosen due to its high protein 
production rate upon cellular infection.  
4.3.3.1 Development of SFV YN-ΔCaMN60DN97D-IRES-VAA-ΔSpF18A-YC- ΔECFP 
Upon transfection of HEK293T cells with the pSCA-Integrator and the pSCA-Helper 
plasmids the expression of the biosensor was confirmed after 2 days (Figure 41B). Transfection 
of dissociated hippocampal neurons with SFV-Integrator I (SFV-I) for 1 - 6 hours did not yield 
any constitutive FP (ΔECFP) fluorescence detected either by western blot (Figure 41A) or by 
fluorescence microscopy (Figure 41B). However, it is important to note that apoptotic cells 
(determined by lack of adhesion or morphology) did exhibit detectable fluorescence.  
 
Figure 41: Western blot analysis and expression characterisation of SFV-I  
A) Western blot analysis of dissociated hippocampal neurons infected with SFV-I for between 1 and 6 
hours using an anti-GFP antibody for the SFV-I and an anti-Tubulin antibody as a control. B) Artificially 
coloured fluorescence images of co-transfected pSCA-Integrator/ pSCA-Helper HEK293T cells and 
infection time-course of dissociated hippocampal neurons for up to 6 hours. Scale bar: 50 µm. 
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Upon apoptosis a characteristic high Ca2+ influx is observed, and with fluorescence in 
apoptotic cells observed it was believed that constitutive FP fluorescence may only be 
achievable once the CaM/CBP forms a Citrine refolded complex. Electrical field stimulation of 
dissociated hippocampal neurons yield an increase in both Citrine (ΔF/F: 2184 ± 86 %) and 
constitutive FP (ΔF/F: 653 ± 42 %) fluorescence (Figure 42B, C). Additionally, an increase in 
Citrine fluorescence was also observed upon excitation with CFP (ΔF/F: 1884 ± 78 %) yielding an 
almost linear FRET increase (ΔR/R: 182 ± 10 %) after 1 hour (Figure 42D). Interestingly, no 
immunoreactivity of the anti-GFP antibody was observed at 42 kDa, corresponding to the VAA-
ΔSpF18A-YC-ΔECFP component. However, time-dependent anti-GFP immunoreactivity was 
observed at 72kDa indicating that constitutive FP fluorescence occurred upon complex 
formation. It must be noted that it was indistinguishable to what extent Citrine and ΔCFP 
separately contributed to immunoreactivity (Figure 42A).  
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Figure 42: Electrical Field Stimulation characterisation of SFV-I  
A) Western blot analysis of dissociated hippocampal neurons infected with SFV-I for a 2 hour 
preincubation before electrical field stimulation for 1 to 4 hours using 80 Hz PF, 1000 µs PW, 1 s BD, 30 V 
FS. An anti-GFP antibody was used detection of SFV-I and an anti-Tubulin antibody was used as a 
control. B) Artificially coloured fluorescence microscopy images of CFP (top panels), Citrine (middle 
panels) and Citrine excited with CFP excitation wavelength of 430 nm (bottom panels). C) Quantification 
of fluorescence of CFP (Blue), Citrine (Yellow) and Citrine excited using 430nm (black). D)   FRET ΔR/R 
over 4 hours.  Scale bar: 50 µm. Error bars ± SD. 
 
Due to the lack of constitutive FP fluorescence it was determined whether incubation 
time possessed any effect on SFV-I activity. To achieve this SFV-I responses to field stimulation 
after either a 2 hour or 16 hour pre-incubation were compared (Figure 43A). A significant 
difference in Citrine fluorescence after 2 and 3 hours was found (Figure 43B). Due to the 
significantly higher complementation observed with a 2 hour compared to 16 hours pre-
incubation, the two hour pre-incubation timeframe was used for all subsequent experiments.   
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Figure 43: Effect of infection duration of SFV-I activity  
A) Artificially coloured fluorescence images of dissociated hippocampal neuron infected with SFV-1 for 
either 16 or 2 hours before experiment initiation. Upon initiation cells were stimulated with electrical 
field stimulation using 80 Hz PF, 1000 µs PW, 1 sec BD, 30 V FS parameters. B) Quantification of 
fluorescence of Citrine after 16 hours pre-incubation (red) or 2 hours pre-incubation (black). **p<0.02, 
***p<0.001. Scale bar: 50 µm. Error bars ± SD. 
 
4.3.3.2 Generation of alternative SFV variants 
To overcome the lack of constitutive FP fluorescence two different approaches were 
undertaken. The first approach was to replace the ΔCFP with either an improved cyan 
fluorescent protein mCerulean 3 (Markwardt et al., 2011) or mCherry (Shaner et al., 2004). The 
second approach was to switch the two components to place the constitutive FP under the 
CMV promoter and the CaM under the IRES promoter (Figure 44A). In vitro Ca2+ titrations 
revealed that replacing ΔCFP for either mCerulean 3 or mCherry resulted in a respective 73 % 
and 64 % reduction of Citrine complementation (Figure 44B). Regardless, three virus variants 
were generated; mCerulean 3 (SFV-II), mCherry (SFV-III) and the reversed component 
orientation (SFV-IV). Transient transfection of HEK293T cells revealed substantial constitutive 
FP fluorescence (Figure 44C top panels); however after 6 hours of viral infection no constitutive 
FP fluorescence was detectable (Figure 44C bottom panels).   
93 Results 
 
 
 
 
Figure 44: Generation of SFV variants SFV-II, SFV-III and SFV-IV.  
A) Schematic of SFV variants. B) Ca2+ titrations of YN-ΔCaMN60DN97D with; black: VAAΔSp-YC-ΔCFP, blue: 
VAAΔSp-YC-mCherry, red: VAAΔSp-YC-mCerulean 3. C) Top panel: Constitutive FP fluorescence of 
HEK293T cells transiently transfected for two days with SFV-II, SFV-III and SFV-IV. Bottom Panels: 
Dissociated hippocampal neurons infected for 6 hours with the respective SFV variant. Scale bar: 50µm. 
Error bars ± SEM. 
 
 
Characterisation of the viruses using electrical field stimulation found a significant 
decrease in Citrine fluorescence of all new variants compared to SFV-I (Figure 45A). 
Interestingly, only the SFV-III displayed any increase in constitutive FP fluorescence that rivaled 
SFV-I (Figure 45B), however, due to the poor performance SFV-I was chosen for continuing 
characterisation.  
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Figure 45: Characterisation of SFV variants SFV-II, SFV-III and SFV-IV  
A) Citrine ΔF/F of SFV-I (black), SFV-II (red), SFV-III (blue) and SFV-IV (green) using 80 Hz PF, 1000 µs PW, 
1 sec BD, and 30 V FS stimulation parameters. B) Constitutive FP ΔF/F for SFV-I (black), SFV-II (red), SFV-
III (blue) and SFV-IV (green). *** p<0.001 
 
 
 
4.3.3.3 Development of physiological Electrical Field Stimulation protocols 
To determine whether SFV-I is responsive to physiologically relevant stimuli it was 
necessary to develop field stimulation protocols that resembled the activity observed in neuron 
populations. Stimulation protocols were developed to resemble spontaneous activity 
stimulation (SAS), Hippocampal CA1 neuron Stimulation (HS) (Garaschuk et al., 1997), Primary 
Afferent neuron Stimulation (PAS) (Enes et al., 2010) and Theta Burst Stimulation (TBS) 
(Balkowiec and Katz, 2002). These stimulation protocols were selected due to the significant 
variability in the intertrain intervals (ITI) that varied from a burst every 10 sec (SAS) to every 5 
min (PAS) (Figure 46A-D). Using the calcium dye Fluo-4 AM a sub-maximal ΔF/F was observed in 
HS, TBS, and PAS, and no detectible Ca2+ transients in SAS (Figure 46E-H). Using the LIVE/DEAD 
cytotoxicity assay we determined no significant effects on cell apoptosis by any stimulation 
protocol (Figure 46I-L).  
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Figure 46: “Physiological” field stimulation protocols  
A-D) Illustration of field stimulation protocols; A: Spontaneous Activity Stimulation (SAS; 1 Hz PF, 150 µs 
PW, 1 s BD, 30 V FS, 10 s ITI), B: Hippocampal CA1 neuron Stimulation (HS; 50 Hz PF, 150 µs PW, 1 s BD, 
30 V FS, 60 s ITI), C: Primary Afferent neuron Stimulation (PAS; 20 Hz PF, 150 µs PW, 20 s BD, 30 V FS, 
300 s ITI), D: Theta Burst Stimulation (TBS; 20 Hz PF, 100 µs PW, 5 s BD, 30 V FS, 20 s ITI). E-H) Fluo-4AM 
ΔF/F using electrical field stimulation protocols outlined in A-D (E: SAS, F: HS, G: PAS, H: TBS). I-L) 
Normalised percentage of cell survival (Live/Dead Cytotoxicity Assay) upon application of electrical field 
stimulation protocols outlined in A-D (I: SAS, J: HS, K: PAS, L: TBS). Error bars ± SD. 
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4.3.3.4 Characterisation of SFV-I using physiological stimulation 
For evaluation of SFV-I performance under physiological stimulation conditions three 
parameters were investigated; the ΔF/F of Citrine, the ΔF/F of the constitutive FP (ΔECFP), and 
the ΔR/R of the FRET response. Regarding the ΔF/F of Citrine and the constitutive FP all 
stimulation protocols (with the exception of SAS) displayed significant increases in fluorescence 
during four hours. The earliest significant increase was observed using TBS, whereby after two 
hours fluorescence was recorded in both Citrine and ΔECFP (Figure 47A, B). HS displayed the 
largest increase in Citrine ΔF/F after four hours (1579 ± 43 %); however it displayed no 
significant increase in constitutive FP fluorescence compared to PAS. Interestingly, TBS yielded 
a maximal Citrine ΔF/F, after three hours, a 51 % increase compared to the Citrine intensity 
observed at four hours using HS. In neither case was significant fluorescence observed using 
SAS. Regarding the FRET response only HS displayed a significant ΔR/R (108 ± 4 % after 4 hours) 
indicating that this virus is unsuitable for FRET-based analysis of all neuronal firing patterns 
(Figure 47C). When stimulation of dissociated hippocampal neurons was inhibited, by the 
application of 1 µM of the voltage-gated sodium channel inhibitor “Tetrodotoxin” (TTX) and the 
L-type voltage-gated Ca2+ channel inhibitor “Nimodipine”, all observed ΔF/F and ΔR/R 
responses were abolished (Figure 47D-F). 
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Figure 47: Characterisation of SFV-I using “physiological” field stimulation protocols  
A-C) SFV-I responses to SAS (black), HS (red), PAS (blue) and TBS (green) stimulation (A: Citrine ΔF/F, B: 
Constitutive FP ΔF/F, C: FRET ΔR/R). D-F) SFV-I responses to SAS (black), HS (red), PAS (blue) and TBS 
(green) stimulation in the presence of 1 µM TTX and 1 µM Nimodipine (D: Citrine ΔF/F, E: Constitutive FP 
ΔF/F, F: FRET ΔR/R). *** p<0.001. Error bars ± SD. 
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4.3.4 Application of Bimolecular Fluorescence Complementation developed protein-
pair for the development of other split-protein based strategies 
The lack of an in vitro platform for the development of the split-TEV protease Integrator 
became one of most pertinent issues for the project’s dismissal. The subsequent 
complementation biosensor development has yield the development of a novel CaM/peptide 
combination that can elicit fluorescence complementation in response to endogenous Ca2+ 
transients. The unique combination developed using Bimolecular Fluorescence 
Complementation was consequently theorised to be applicable to other split-protein strategies 
such as the split-TEV. To this end, the Citrine fragments were replaced with the aforementioned 
TEV fragments. When the transfected components (along with TS-FRET) were subjected to field 
stimulation a 35 ± 2.7 % decrease in the FRET ratio was observed after 2 hours (Figure 48). 
Thus, not only has the first complementation-based Integrator been engineered to respond to 
endogenous factors but also the successful application of complementation-engineered 
proteins to other split-protein based strategies (that cannot be developed in) has been 
demonstrated.  
 
Figure 48: Split-TEV responses to field stimulation using TS-FRET  
FRET ΔR/R values for transfected dissociated neurons stimulated for 2 hours with a stimulation burst (80 
Hz PF, 1000 µs PW, 1 sec BD, 30 V FS) every 4 minutes. Stimulation of ΔCaM/ΔM13 (red) or unstimulated 
(black) compared to stimulation of ΔCaMN60DN97D/VAAΔSpF18A (green) or unstimulated (blue). Error bars 
±SD. 
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5 Discussion 
5.1 Overview of Integrator development 
In order to generate the Integrator biosensor three primary concept designs were 
undertaken with each being discussed in detail below. In brief the three designs considered 
were the development of; a Ca2+-dependent protease FRET integrator, an artificial Ca2+-
dependent protease with FRET reporter (via either the development of a conformation-
dependent TEV Integrator or a split-protein based Integrator), and a complementation 
Integrator. Of the three models the Bimolecular Fluorescence Complementation design 
satisfied all in vitro criteria and, as a consequence of this, the complementation Integrator was 
the only design pursued for further development (Figure 49). Furthermore, it is important to 
note that a complementation-based strategy can also be used for the development of other 
split-protein based strategies.  
 
Figure 49: Summary of Integrator design concepts 
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5.2 Approach 1: Ca2+-dependent protease FRET Integrator 
Initial approaches in the development of an irreversible Ca2+-dependent Integrator were 
formulated on the concept of utilising proteases, whether intrinsically Ca2+-dependent or not, 
to induce the irreversible cleavage of a FRET pair. The first approach took the notion that using 
the Ca2+-dependent protease µ-Calpain, and the previous research identifying a µ-Calpain 
responsive FRET-pair, an Integrator could be engineered and tailored for the integration of 
neuronal Ca2+ transients. The proposed approach to this design was to engineer an improved µ-
Calpain with an oestrogen receptor ligand binding domain (ER-LBD) that would result in the 
nuclear translocation of the protease by the administration of the synthetic ligand Tamoxifen. 
By the addition of a nuclear localisation sequence (NLS) to the FRET-pair the FRET substrate 
could be restricted to the nucleus.  
The first step in any biosensor design is the establishment of an in vitro platform from 
which further design modifications could be verified. Without previous publications providing 
insight into the development of this platform, purified µ-Calpain was chosen for the 
characterisation of the FRET-pairs; CSS (Calpain Sensitive Substrate FRET pair) and CIsS (Calpain 
Insensitive Substrate FRET pair). In the presence of 1 mM Ca2+ the CSS displayed the largest 
reduction in FRET ratio. However, in contrast to previous research the CIsS also displayed a 
certain degree of Calpain specificity. The residual activity demonstrated by the CIsS can most 
likely be attributed to the neighbouring C-terminal glycine as µ-Calpain is known to cleave 
between the Tyr5 and Gly6 residues (Harris et al., 1988). Whilst this residual activity was a minor 
consideration (as the CIsS could easily be re-engineered to remove this activity) it validated the 
sensitivity of the in vitro platform.   
With the established in vitro platform the development took on a bifurcated approach 
to determine the physiological Ca2+ range of the CSS and the engineering of a µ-Calpain 
construct from cDNA. Using purified µ-Calpain a minimal threshold of between 10 and 100 µM 
Ca2+ was observed, in agreement with previous literature (Dutt et al., 2002). The discrepancy 
between in vitro and in vivo Kd measurements have been reportedly due to the large CAPN1 
subunit with various hypotheses postulating Calpain/phospholipid complexes or highly localised 
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Ca2+ concentrations to be the source of this discrepancy. Nevertheless, the attempts at 
engineering a µ-Calpain construct focused on either combined expression with a constitutive FP 
(mCherry) or IRES-separated expression of the two subunits. The lack of active µ-Calpain 
protease isolated from four constructions (µ-C1-4) significantly hindered the development of 
the Integrator concept that ultimately was discontinued in favour of alternative approaches.  
 
5.3 Approach 2: Artificial Ca2+-dependent protease with FRET reporter 
The second approach towards development of an integrator was the generation of an 
artificially Ca2+-dependent protease that would cleave a FRET reporter in a similar fashion to the 
µ-Calpain based Integrator. The two strategies considered were either the development of a 
conformation-dependent protease Integrator or a split-protease Integrator. The protease 
selected for this approach was the TEV protease (Tobacco Etch Virus) due to the lack of 
identified mammalian homologs and its well-defined substrate (van den Berg et al., 2006).  
For the conformation-dependent protease Integrator it was postulated that, by using a 
Transposon insertion mechanism, locations within the protease structure could be identified for 
the insertion of a Ca2+ responsive element that would confer protease activity upon Ca2+ 
binding. The high affinity C-lobe (EF-hands III and IV) of Troponin C (TnC) was chosen as the Ca2+ 
responsive element over the architecture favoured by the GCaMP biosensor series due to the 
small size of the C-lobe that would limit the perturbation of protease function. The initial stages 
of this design were the modification of the TEV protease to improve kinetics and to identify the 
positions for TnC insertion. By removal of the auto-inhibitory C-terminal domain and the 
addition of a mCherry Reporter the Kd improved 760 %. Furthermore, the screening of 
randomly inserted Transposons yield a bias of insertions between amino acids 170-210 that 
retained mCherry  fluorescence. It can be speculated that insertions outside of this upper- and 
lower- quartile yield misfolded protease that, in turn, resulted in misfolded mCherry. The 
random selection of insertion sites did yield both TEV protease variants retaining proteolytic 
function and variants without function. However, once TnC was inserted into these selected 
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sites a Ca2+-free and Ca2+-dependent increase in FRET was observed. The exact source of the 
observed increase in FRET was not been fully identified, however, it was most likely a result of 
protease/substrate binding in the absence of protease function. At this point this approach was 
discontinued; nonetheless, several avenues remain open to investigation. Primarily, generation 
of TEV cp-variants at these locations may provide the initial framework for the development of 
an Integrator resembling the GCaMP architecture. Furthermore, one could additionally look at 
the applicability of inserting other EF-hands motifs that possess alternative structural 
conformations that may enable the gain of function, for example the FrpC Ca2+-binding domain 
(Osicka, 2004).  
The second approach using the TEV protease was based on the research from Moritz 
Rossner whereby they could recover protease function from split-TEV by inducing FRB/FKBP 
heterodimerisation via rapamycin addition (Wehr et al., 2006). It was expected that by the 
substitution of the proteins FRB/FKBP for ΔCaM and ΔM13 a Ca2+-dependent split-protein 
Integrator could be developed. To this end several orientations of components were 
investigated in vitro with no significant change in the FRET ratio of TS-FRET observed. Once no 
FRET cleavage was observed using an alternative rapamycin-induced heterodimerisation of 
FKBP-N-TEV and FRB-C-TEV it was concluded that the in vitro platform was not appropriate for 
studying recombined protease function. To circumvent this, a cell culture stimulation platform 
was developed for the reliable stimulation of neurons (electrical field stimulation). NT-CaM and 
M13-CT were tested using high frequency bursts every 4 min and no significant change in TS-
FRET ratio was recorded after 2 hours. With the inability to develop this concept in vitro and the 
lack of protease function in cell culture this split-protein approach was discontinued.  
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5.4 Approach 3: Bimolecular Fluorescence Complementation Integrator 
The third approach explored was the application of Bimolecular Fluorescence 
Complementation that had previously been successfully demonstrated in vitro (Hu et al., 2002). 
Through the application of split-FP architecture several advantages would be conferred over 
split-protease based approaches. Primarily the reduction of the overall size of the Integrator as 
this would obviate the requirement of a FRET reporter. Secondly, due to the single wavelength 
signal the ΔF/F can be engineered to yield a significantly greater signal than the ΔR/R FRET 
changes elicited by FRET-pair cleavage. 
 
5.4.1 In vitro optimisation of split-FP Integrator 
The first step in generating the complementation Integrator was the development of a 
suitable biosensor architecture from which further optimisation could be pursued. Two 
locations were chosen to split the FP, at amino acid positions 155 or 173 (Hu and Kerppola, 
2003). Upon fusion to ΔCaM and ΔM13 it was observed that the 154/155 split yield the highest 
signal (Ca2+-dependent complementation). As both locations exhibited similar background 
fluorescence, it was necessary to identify whether the responsible interaction was due to the 
ΔCaM/ΔM13 interaction or due to the split-FP interaction as it has been demonstrated that 
split FPs can display high levels of self-assembly (Cabantous et al., 2005). Purification of the FP 
fragments alone led to the identification of the ΔCaM/ΔM13 interaction as being responsible 
for the background fluorescence observed. By exchanging the mutant form of CaM and M13 for 
wild-type variants, a significant reduction in the overall signal level was noted. Furthermore, 
signal was abolished when the mutant and wild-type variants were used in combination. Thus it 
was demonstrated that the specificity of the ΔM13 for ΔCaM was of an intrinsic value that 
would determine the success of the Integrator and, by architectural optimisation, one could 
reduce the spontaneous association between the two components. 
The first optimisation strategy aimed to determine the optimal orientation of the 
Integrator components that would yield the largest signal with the lowest background. 
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Orientation screening determined the optimal orientation to be the original YN-ΔCaM/ΔM13-
YC, in agreement with structural data. The ensuing step was the replacement of Citrine with 
alternative FPs in order to minimise background fluorescence whilst maintaining high signal. Of 
the FPs examined (CFP, mKO, mKO2, mOrange, mCherry, mKate and Tag RFP) the only other 
combination that demonstrated in vitro fluorescence was YN172/ CC155. This combination  
resulted in a FP hybrid of CFP and Citrine with an additional β-sheet and, even though this 
phenomenon had previously been observed (Hu and Kerppola, 2003), the surprisingly large 
increase in signal was unforeseen. However, due to the substantial increase in background 
fluorescence this combination was dismissed as a suitable alternative for the Integrator.  
With the selection of the most suitable orientation and the most suitable FP completed 
the cellular expression of the Integrator found significant Citrine fluorescence after 16 hours in 
approximately 35 % of cells. Furthermore, when dissociated hippocampal neurons were 
subjected to the same stimulation parameters as the split-TEV approach (with a burst every 4 
min) no significant increase in Citrine fluorescence was observed.  
At this point a screen of all currently identified Ca2+-dependent CaM binding peptides 
was undertaken in order to identify peptides which were better suited for this Integrator 
approach. The benefit of such a strategy was that it enabled the screening of a variety of 
peptide recognition motifs (classified according to the hydrophobic anchor residues). For 
example, by screening a range of peptides, such as the M13 peptide that exhibits a 1-5-8-14 
recognition motif or CaMKKβ that exhibits a 1-16 recognition motif, one could determine 
whether a particular motif bias is preferential for the Integrator (Yamniuk and Vogel, 2004). 
When generating the CaM peptide-YC component a PCR error led to the inclusion of a 
ΔSpectrin peptide lacking a Histidine at position 14. After 4-hour incubation the ΔSpectrin 
peptide displayed the highest level of complementation with low background fluorescence that 
outperformed the original ΔM13 peptide. Using more sensitive cuvette based experiments a 
significant improvement in signal was observed with an additional reduction in background 
fluorescence. These characteristics were also reflected in cell culture experiments where 
ΔSpectrin exhibited a significant reduction in population of cells exhibiting background 
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fluorescence and an overall decrease in the fluorescence intensity. Interestingly, Spectrin and 
M13 possessed a very similar recognition motif (Spectrin: 1-8-14), and the majority of peptides 
that displayed signal also belonged to one of these two classes. Even though no conclusive 
explanation can be offered as to the origin of this specificity observed, the similarity of CaM 
from structural data of complexes of CaM/M13 and CaM/Spectrin was investigated. A 
comparison of the N-termini from CaM/M13 (PDB: 3EK4) and CaM/Spectrin (PDB: 2FOT) found 
little variation in CaM orientation (Root Mean Squared Deviation (RMSD) of 0.743), whereas we 
found a slightly larger RMSD of 1.168 when comparing the C-termini (Figure 50). Whilst the C-
termini comparison lacks one EF-hand (due to incomplete sequences) this structural deviation 
cannot wholly account for the discrepancy in signal observed. Thus, the most likely explanation 
is that by shortening the Spectrin peptide by one amino acid the bump-and-key remodelled 
CaM forms complexes with a favoured orientation for complementation.  
 
Figure 50: Structural comparison of CaM when bound to M13 or Spectrin 
A) N-terminal and B) comparison of CaM in complex with M13 (green) or Spectrin (blue). Red spheres 
denote Ca2+ ions. The incomplete structure shown in B is due to incomplete PDB data. Green: PDB 3EK4, 
Blue: PDB 2FOT.  
 
In possession of an improved peptide a further attempt to improve the 
signal/background ratio was undertaken by the modification of the Citrine fragments. Shifting 
the fragmentation site or the addition/removal of an extra amino acid led to the hypothesis 
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that the background fluorescence could be reduced by the induction of sub-optimal 
complementation. Interestingly a 27 % increase in signal accompanied the expected 22 % 
reduction in background fluorescence when the fragmentation site was shifted from 154/155 to 
153/154; suggesting an improved separation site. Contrastingly, addition or removal of an extra 
amino acid facilitated the formation of background fluorescence and inhibited signal.   
Using the improved separation location the investigation of Integrator function at higher 
temperatures was performed, as previous research had implicated a temperature-dependent 
effect on complementation (Robida and Kerppola, 2009). Two approaches were undertaken to 
try and differentiate between temperature-induced effects on complementation and 
ΔCaM/ΔSp interaction; i) the incubation of the two components in a Ca2+-saturated solution at 
different temperatures, to determine the effects of temperature on complementation, and ii) 
subjection of the two components to more physiologically relevant Ca2+ concentrations, in 
order to determine the effects of temperature on CaM/Ca2+ binding. Hereby, it was found that 
no significant in vitro reductions in complementation were observed upon incubation of the 
two components in Ca2+-saturated solution. In contrast, a progressive reduction in background 
fluorescence was observed using a series of Ca2+ titrations that was concluded to be a reduction 
in the spontaneous association of ΔCaM/ΔSp. In agreement with the previously observed 
reduction in background fluorescence a significant decrease in the total complementation was 
noted when subjected to physiologically relevant Ca2+ which suggested that increased 
temperature either reduces the ΔCaM/ΔSp interaction alone or additionally reduces the 
CaM/Ca2+ binding. Thus, by experimental design one could not distinguish between the affinity 
of Ca2+ for CaM and the ensuing affinity of CaM for the peptide. Despite this reduction in Ca2+ 
affinity it was unclear, at this point, whether functional interactions between ΔCaM/ΔSp could 
occur in a cellular environment. Exposure of HEK293T cells to a 4 hour Ionomycin and Ca2+ 
treatment resulted in an increase in complementation indicative of functional interaction of 
ΔCaM/ΔSp. However, subsequent exposure of dissociated hippocampal neurons to intracellular 
Ca2+ transients via field stimulation did not yield any recorded complementation.  
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5.4.2 Complementation Integrator refinement for response to endogenous Ca2+ 
transients 
With the generation of a complementation-based Integrator responsive to exogenous 
Ca2+ application the next step was the further refinement of the Integrator in order to elicit a 
complementation response to endogenous Ca2+ transients. With optimisation of the 
fundamental architecture already completed the only avenue remaining for architectural 
modification was the addition of linkers between the components as this had been previously 
shown to increase biosensor Ca2+ affinity (Horikawa et al., 2010). To achieve this, variants of the 
components were generated to incorporate poly-glycine linkers in order to increase the 
rotational freedom of ΔCaM or ΔSp with their corresponding Citrine fragment. Although the 
addition of the majority of linkers to YN-CaM or ΔSp-YC components inhibited 
complementation, the incorporation of the poly-glycine linker “GGGGS” in-between ΔSp and YC 
did yield a 31 % improvement in complementation. Nevertheless despite this improvement no 
linker addition conferred an improvement to Ca2+ affinity.  
An alternative approach to increase the Ca2+ affinity was undertaken based on the “Acid 
pair hypothesis” that correlates Ca2+ affinity with the position of acidic residues in chelating 
positions of the EF-hand Ca2+ binding loop (Tikunova et al., 2001). For this approach, a single or 
double substitution of the +Z chelating position in CaMs EF-hands II and III (N60D and N97D 
respectively) was performed to replace the amide amino acid (Asparagine) for an acidic amino 
acid (Aspartic Acid). On the one hand, the N60D mutation in the low-affinity “structural” N-lobe 
significantly improved signal but did not confer increased Ca2+ affinity. Moreover, the N97D 
single mutation in the high-affinity “regulatory” C-lobe decreased the overall signal and again 
conferred no improvement to affinity. However, in contrast to the single substitutions, the 
combination of the substitutions significantly improved not only the signal but also significantly 
improved the affinity (with an EC50 improvement from 2000 nM to 1460 nM). Despite these 
substitutions not correlating to improved EF-hand behaviour (as only the adjacent EF-hand in a 
lobe has any influence in the affinity of the other EF-hand), they suggested a dynamic process 
whereby improving Ca2+ coordination in the structural lobe leads to improved peptide binding 
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that requires the additional Ca2+ affinity improvement in the regulatory lobe for improved 
complementation.  
Due to the CaM mutations requiring modification of the structural lobe it was also 
necessary to investigate whether the addition of the linker that provided slight signal 
improvement (ΔSp-GGGGS-YC) would complement these CaM modifications. When combined 
the improved performance of CaMN60DN97D was abolished and the Ca2+ affinity was also reduced. 
From this observation it was determined that additional flexibility conferred by the integrated 
linker improved the orientation of the Citrine fragments. However, the additional modification 
of the CaM/ΔSp interaction surface did not exhibit this improved orientation when combined 
with the linker. Consequently, as the improved characteristics of CaMN60DN97D outweighed the 
linker-improved characteristics the linker was dismissed in favour of the CaM mutations.  
During the course of improving the Integrator’s architecture experimental observations 
led to the conclusion that the ΔSp-YC component, consisting of a 22 amino acid peptide fused 
to the 84 amino acid C-terminus of Citrine, was prone to degradation. In order to improve this 
component’s cellular translation efforts to improve the N- and C-terminus were undertaken. 
The motivation behind C-terminus stabilisation was twofold, the first was the reduction in 
proteasomal degradation, and the second was that through addition of CFP it would obviate the 
requirement for additional transfection of CFP. Two CFP variants were selected, the enhanced 
CFP (ECFP) and ΔECFP, an ECFP variant that contained the improved folding mutations S30R and 
Y39R, and the monomerisation mutation A206K (Pédelacq et al., 2006). By comparison of the 
signal behaviour of the two ECFP variants it was anticipated that, not only would this contribute 
to the fundamental understanding of Bimolecular Fluorescence Complementation, but also 
determine the applicability of the Integrator as a ratiometric FRET biosensor. The determination 
of the concentration-corrected excitation and emission fluorescence spectra revealed 
significant differences in CFP fluorescence with ΔECFP possessing significantly higher 
proportions of correctly folded FPs compared to ECFP. This observation was also reflected by 
Ca2+ titrations (with YN153-CaMN60DN97D), that found increased signal with the inclusion of 
ΔECFP without improvement of Ca2+ affinity. Interestingly, both the ΔECFP and the poorer 
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performing ECFP elicited similar FRET ΔR/R changes that, not only confirmed the 1:1 
stoichiometry of CaM/CBP interaction, but also confirmed the belief that complementation 
based architectures retain significantly higher responses as single fluorophore biosensors than 
as ratiometric biosensors.  
In tandem, N-terminal modification of ΔSp were undertaken in accordance to the “N-
End Rule” that stipulates that the in vivo half-life of a protein is related to the identity of its N-
terminal residue (Varshavsky, 2008). Primary destabilisation of ΔSp was reduced via the 
incorporation of several N-terminal sequence caps that possessed a Valine followed by a varied 
number of Alanine residues (V, VA, VAA, and VAAA). To validate stabilisation, two parameters 
were evaluated; the Integrator response and the quantification of component degradation via 
the ubiquitin pathway. Ca2+ titrations yield varied signal responses with no correlation of 
response to N-cap length. Nevertheless, the VAA-ΔSp (KT) demonstrated the most optimal 
increase in signal with a significantly improved Ca2+ affinity. By comparison of CFP fluorescence 
under normal and proteasome inhibition conditions all N-terminal modified component 
demonstrated an almost 100 % reduction in proteasomal degradation. Understandably, the 
length of the N-terminal cap was not correlated to proteasomal degradation reduction. From 
the two parameters investigated it was concluded that despite the N-terminal cap conferring 
significant stability to the component the length of the cap played a significant role in the 
alteration of Integrator function. Furthermore, ΔECFP replacement with ECFP exhibited a 
significant increase in proteasomal degradation, thus highlighting the beneficial significance of 
folding-optimised C-terminal structured elements in the provision of structural stability during 
translation. 
The final step of Integrator development was the introduction of Alanine mutations that 
had previously been shown to have profound effects on the affinity of the M13 peptide for CaM 
(Montigiani et al., 1996). Whilst the published research could not be directly extrapolated (due 
to the modified ΔCaM/ΔSpectrin interface and the multi-factorial readout of complementation) 
a selection of 5 mutations were selected spanning from residue K7 to S20. In vitro analysis 
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found no direct correlation between complementation and the previously published results; 
however one mutation, F18A, conferred a significant improvement to signal and Ca2+ affinity.  
Due to the incorporation of several modifications to the Integrator’s design, since the 
initial proof-of-concept experiment, several points of characterisation were required. Firstly, 
the most fundamental criteria of the Integrator concept was re-validated, namely the 
confirmation that this architectural approach confers an irreversible Ca2+-dependent response. 
Addition of the Ca2+ chelating agent BAPTA after either 0.5 or 1 hour proved that the almost 
instantaneous cessation of complementation was maintained without any observed reduction 
in fluorescence. Furthermore, the in vitro kinetics implied an almost linear increase in 
complementation between 0 and ~400 nM CaCl2, whereas higher Ca
2+ concentrations (up to 
1.1µM) achieved a more saturated rate of complementation after 4 hours. Secondly, cell 
characterisation of the modified VAA-ΔSpF18A peptide was undertaken in HEK293T cells to 
compare the background fluorescence of the VAA-ΔSpF18A peptide with the previously 
characterised ΔSp and ΔM13 peptides. In comparison to ΔSp the VAA-ΔSpF18A peptide exhibited 
an increased percentage of cells expressing background fluorescence (that was comparable to 
ΔM13) whilst maintaining a similar background fluorescence intensity to the ΔSp peptide.  
With the substitution of the Citrine fragments for ECFP and Citrine the CaM/CBP 
modifications were validated on a cell-based platform by the observation of a 285 % increase in 
FRET ΔR/R of ΔCaMN60DN97D/VAA-ΔSpF18A when compared to the original ΔCaM/ΔM13. As no 
significant difference was observed in the starting ratio of each pair of interacting proteins, it 
was concluded that the higher ΔR/R observed upon stimulation of ΔCaMN60DN97D/VAA-ΔSpF18A 
was due to an improved CaM/CBP interaction. Furthermore, FRET studies of the VAA-ΔSpF18A 
with wtCaM yielded negligible elevation in ΔR/R suggesting a high degree of specificity of the 
modified peptide for ΔCaMN60DN97D. 
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5.4.3 Summary of complementation Integrator development 
During the initial planning stages of the complementation integrator a mechanism was 
proposed demonstrating the process by which this Integrator would function (Figure 10). 
During the course of development, not only has the fundamental architecture been improved, 
but also the characteristics of each Integrator component. Thus, the initial mechanism was 
found to represent a simplified idea of what was effectively a very complex process. In order to 
fully appreciate this complexity a more realistic mechanism has been developed (Figure 51) 
and, when appropriate, some explanation has been offered as to how these modifications have 
improved the Integrator.  
 
Figure 51: Proposed mechanism of complementation Integrator Activation  
Proposed schematic of the interaction of Citrine fragments (YN and YC) fused to CaM and the ΔSp. For 
clarity the CFP is only shown in the top right.  Kcomp: competition of CaM and the CBP for endogenous 
CBP’s or wtCaM respectively. F1 pathway: mechanism for spontaneous association; K
1
assoc: spontaneous 
association of apo-CaM and ΔSp, K1diss: dissociation of apo-CaM and ΔSp. K
1
mature: maturation of Citrine.  
F2 pathway: mechanism for Ca
2+ dependent complementation; K2on: rate of Ca
2+ binding to CaM, K2off: 
rate of CaM-Ca2+ dissociation, K2bind:  rate of CaM- ΔSp binding, K
2
diss: rate of CaM- ΔSp disassociation, 
K2mature: maturation of Citrine. 
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To summarise the development of the complementation Integrator one can separate 
improvements into two categories: i) modifications to refine the Integrator architecture and ii) 
modifications that improve component/Integrator performance. Refinement of this biosensor 
architecture has been achieved in several ways with the most significant improvement coming 
from the stabilization of the ΔSp-YC component via the addition of a C-terminal CFP and the 
removal of the exposed N-Degron. In addition, the optimisation of component orientation and 
the FP selection also contribute to the refinement of the fundamental Integrator components. 
Furthermore, significant modifications have been made to directly affect the mechanism of 
Integrator activation. Through the identification that the high background fluorescence (K1assoc) 
was due to the ΔCaM/ΔM13 affinity the peptide screen reduced this (or improved K1diss) whilst 
enhancing the Ca2+-dependent CaM/peptide interaction (K2bind). Shifting the fragmentation site 
to 153/154 improved Integrator performance by increasing the signal (K2mature), whilst reducing 
the background fluorescence (K1mature). EF-Hand mutations of ΔCaM have led to improved Ca
2+ 
coordination (K2on) and the ΔSp
F18A mutation has also improved the CaM-ΔSp interaction 
(K2bind). Finally, by developing the Integrator based on mutant forms of CaM a significant 
reduction of wtCaM interaction with the ΔSp peptide (Kcomp) has been achieved. 
 
5.4.4 Functional validation and virus characterisation  
The two components of the Integrator, YN153- ΔCaMN60DN97D and VAA-ΔSpF18A-ΔECFP, 
were placed under the respective CMV and IRES promoters and using electrical field stimulation 
a 223 % increase in Citrine fluorescence was detected over the course of 1 hour using live cell 
imaging. Similarly, when field stimulation was applied to populations of neurons, not under 
constant observation, it was possible to resolve the ratiometric difference (the ratio of 
Citrine/CFP excited with a respective 515 nm and 432 nm) after only 1 hour. This provided 
important validation of one of the most fundamental principles behind the Integrator concept, 
namely the possibility to differentiate between active and non-active neurons after a certain 
period of time. Furthermore, by the observation of marginal signal when ΔCaMN60DN97D was 
substituted for wtCaM it was verified that, not only was wtCaM unsuitable for FRET-based 
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interactions with VAA-ΔSpF18A (as mentioned above), but also unsuitable for eliciting 
complementation.  
With successful demonstration of Bimolecular Fluorescence Complementation in 
response to endogenous Ca2+ transients the final stage in Integrator development was the 
introduction of a mechanism for inducing Integrator expression. For this the alphavirus Semliki 
Forest Virus (SFV) was chosen due to the rapid onset and high expression of the protein of 
interest. When the virus was expressed for 1 to 6 hours no constitutive FP fluorescence was 
observed (despite the presence of ΔECFP fluorescence in HEK293T cells used to generate the 
virus). With the lack of expression additionally confirmed by western blot, a 2 hour pre-
incubation time was applied based on the expression of other viruses (incorporating a different 
class of biosensor) generated in tandem. When field stimulation was applied for 1 to 4 hours, 
increases in both ΔECFP and Citrine fluorescence as well as Citrine fluorescence when excited 
with the CFP wavelength (indicating FRET), were observed. Validation of expression by western 
blot also yield no FP immunoreactivity at 42 kDa (the size of VAA-ΔSpF18A-ΔECFP) but significant 
immunoreactivity at 72 kDa that corresponded to the complex of YN153- ΔCaMN60DN97D and 
VAA-ΔSpF18A-ΔECFP.  
To overcome the lack of constitutive FP fluorescence two approaches were undertaken; 
either the replacement of ΔECFP (SFV-I) with mCerulean 3 (SFV-II) or mCherry (SFV-III), or by 
placing the constitutive FP component under the CMV promoter (SFV-IV). In vitro analysis of the 
replaced constitutive FP did not demonstrate improved Integrator performance and cell-based 
characterisation of both approaches did not confer any improvement in signal. Interestingly, 
the mCherry substitution did not show any significant improvements in constitutive FP 
fluorescence despite the fact that mCherry is not a suitable FRET donor unlike the CFP variants 
ΔECFP and mCerulean 3. As none of the modified viruses displayed significant improvements 
SFV-I was chosen to be subjected to stimuli protocols mimicking physiological firing patterns. 
SFV-I behaviour under different stimulation protocols showed significant constitutive FP 
fluorescence when using TBS, a fact that was not found using other stimulating patterns. Thus, 
this suggests that highly repetitive or very active neurons can be differentiated from less 
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frequently active neurons via the constitutive FP alone. On the other hand, signal was observed 
in all cases with substantial increases in fluorescence observed from between 2 and 4 hours 
except for the control spontaneous firing condition (SAS). In the majority of stimulations (SAS, 
PAS, and TBS) no significant FRET responses was observed.  However, a significant FRET 
response was observed using HS which may provide an indication of regular “medium firing” 
neurons in an in vivo setting. Taken together, these findings implicate a range of possible 
readout mechanisms to differentiate between diverse firing patterns of neurons. Furthermore, 
by the abolishment of neuronal response to field stimulation using sodium/ Ca2+ channel 
blockers it was verified that the signal responses, elicited using the various stimulus patters, 
were indeed due to neuronal Ca2+ transients. 
At this point a virus-induced Bimolecular Fluorescence Complementation Integrator has 
been developed to elicit a stimulation-dependent signal response in cell culture. However, the 
precise origin for the observed lack of constitutive FP fluorescence remains elusive. At present 
there are several hypotheses as to why no fluorescence was observed and these can be divided 
into two groups; the first being a lack of fluorescence and the second (and more likely) being a 
lack of expression. The two possibilities as to why fluorescence is not detectable are either due 
to the IRES promoter or that there is almost complete FRET from the CFP to the Citrine. The 
first possibility, the poor promoter-driven expression, is unlikely as not only has previous 
research incorporated IRES promoters within SFV expression cassettes (Ehrengruber et al., 
1999), but also by placing the constitutive FP under the CMV promoter no improvement to 
constitutive FP fluorescence was observed. The second possibility, that the CFP undergoes 
complete FRET with Citrine, is also unlikely as replacement of ΔECFP with either an improved 
cyan variant (mCerulean 3) or a FRET unsuitable FP (mCherry) did not result in an improved 
performance of the Integrator in vitro or in cell culture. The second group of possibilities relies 
on the lack of FP expression, a concept partially validated via the lack of FP immunoreactivity of 
virus-infected cells. The first explanation of why this is observed is that, unlike transient 
transfection of DNA where transcription and translation occur in the transfected cell, viral 
infection requires the translation of a genomic RNA sequence packed within the virus particle. 
Thus, it is conceivable that the transcription for viral packaging may be the root of the lack of 
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constitutive FP expression. The second explanation is that  although the SFV packaging limit has 
been reported to be 3.5 Kb (DiCiommo et al., 2004) the most likely cause for the lack of 
constitutive FP expression is that the Integrator has exceeded the packaging limit for reliable 
SFV production. 
As a consequence of these observations the next progression from here can be 
separated into two avenues. Firstly, the performance of SFV-I must be determined in vivo to 
ascertain whether constitutive FP fluorescence is observed when placed in an active neuronal 
environment. Therefore, evaluation in vivo will be the primary goal of the proceeding research.  
Secondly, generation of alternative viruses, such as the Adenovirus or Lentivirus viral systems, 
may provide not only suitable alternatives for the induction of Integrator expression but also 
diversify the possibilities of Integrator application based on production duration or whether 
integration into the host genome is desired.   
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6 Conclusion 
 
The research presented here has laid the foundation for the development of a novel 
type of biosensor for the study of functional neuroanatomy via the cumulative integration of 
Ca2+ transients. Three architectural approaches were considered that have highlighted not only 
the criteria necessary for generating this novel class of biosensor but also the parameters by 
which such Integration biosensors should be developed.  
Of the three approaches undertaken, the Ca2+-dependent protease FRET integrator and 
the artificial Ca2+-dependent protease FRET Integrator were unable to be established in vitro. 
However, the split FP-based Bimolecular Fluorescence Complementation Integrator was 
successfully engineered to possess an EC50 of 420 nM. Using a unique CaM/peptide pair 
developed specifically for split-FP interactions it has been shown that a 285 % higher FRET ΔR/R 
interaction is achieved in comparison to the initial ΔCaM/ΔM13 pair. Furthermore, the minimal 
specificity of the modified peptide for wtCaM is indicative of a significantly redesigned 
CaM/peptide interface that is unperturbed from endogenous protein interference. Using a SFV 
induction system the complementation Integrator exhibited a 1580 % increase in Citrine 
intensity after 4 hour stimulation using stimulation parameters resembling physiological firing 
patterns. Furthermore, the successful application of a virus-induced complementation 
Integrator has been shown to successfully differentiate between distinct physiological firing 
patterns with a multitude of readout capabilities. Additionally complementation can be 
demonstrated to be a suitable method for the in vitro development of protein-protein 
interaction pairs that can be further applied to other split-proteins strategies.   
To summarise, the development of this complementation-based Integrator has not only 
equipped researchers with a novel genetically encoded biosensor but also, with the additional 
temporal control of SF-I, a ready-to-use method for the study of functional neuroanatomy in 
vivo. 
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